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ABSTRACT
 Group 1 and 2 house dust mites (HDM) allergens elicit IgE response in more than 
80% of sensitized individuals. These allergens affect 10-30% of the world’s population. 
Prolonged inhalation of low doses of allergens (microgram amounts inhaled over months 
or years) by genetically predisposed individuals leads to the induction of a Th2-type 
immune response induced by allergen-specific immunoglobulin E (IgE) produced by 
plasma cells resulting in allergic diseases like asthma, atopic dermatitis, and rhinitis. Group 
1 and 2 HDM allergens, in particular, are associated with the development of the 
aforementioned allergic diseases. The goal of this research was to characterize properties 
of Group 1 and 2 HDM allergens related to their structure, function, and interactions with 
monoclonal antibodies (mAbs). Structural studies, specifically X-ray crystallography, were 
used to identify important residues responsible for antigen-antibody interactions. Protein 
characterization and analysis of the antigenic surface of these allergens enabled the design 
of allergen mutants with defined three-dimensional structure, reduced IgE reactivity, and 
retained T cell epitopes for production of hypoallergens to be utilized in HDM allergy 
immunotherapy.  
Another family of allergens studied in this research were profilins. This family 
shares high amino acid sequence identities and similarities even between distantly related 
members. This sequence homology can lead to IgE cross-reactivity resulting in pollen-food 
syndrome. Details on protein production, thermal stability, and allergen sensitization 
studies in patients with pollen-food syndrome are presented herein. Understanding the 
vi 
immunological, molecular, and structural properties of profilins will demystify the clinical 
importance of profilins in pollen-food syndrome.  
Lastly, in this research, a new robust way of predicting IgE cross-reactivity between 
two allergens belonging to the same protein family was developed. The A-RISC index 
(Allergens’–Relative Identity, Similarity and Cross-reactivity) results in a single numerical 
value which enables the likelihood of IgE cross-reactivity to be grouped into four 
categories: high, medium-high, medium-low and low. The proposed approach can facilitate 
analysis in component-resolved allergy diagnostics, generate avoidance guidelines for 
allergic individuals, and assist with the design of immunotherapy. This research will 
facilitate future immunotherapy, vaccine design and component-resolved allergy 
diagnostics in not only profilins and HDM allergies, but in all other relevant types of 
allergies.
vii 
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Nearly 50 million Americans suffer from allergies, constituting them as the sixth 
leading cause of chronic illnesses in America [1].  Worldwide, about 30-40% of the world’s 
population suffer from one, or more allergic conditions [2].  Allergies are a hypersensitivity 
to normally harmless substances.  When this happens, these harmless substances are 
denoted as allergens.  Exposure to low doses of allergens over time primes a patient’s Th2-
type immune response with allergen-specific immunoglobulin E (IgE) production by 
plasma cells, which then leads to allergic diseases [2].  There are many types of allergens 
present in the world, emanating from a plethora of sources.  The sources include, but are 
not limited to, drugs, food, pollen and dust; they can be inhaled, ingested, injected, and/or 
contacted [3]. To make it easier for both researchers and clinicians to navigate through the 
“jungle of allergens”, more than three decades ago, formal allergen nomenclature was 
created. Allergen names are composed of an abbreviation of the scientific name of its 
source (genus: 3–4 letters; species: 1–2 letters) and an Arabic numeral. For example, an 
allergen from chicken, Gallus domesticus, is named Gal d 1 [4]. 
Currently, there are over one thousand allergens identified and registered with the 
World Health Organization and International Union of Immunological Societies 
(WHO/IUIS) Allergen Nomenclature Sub-committee. These allergens are distributed 
between 151 families [3]. Interestingly, allergens arise from relatively few protein families 
which represent only a small fraction of the protein families described in the Pfam database 




to be an allergen if it induces an IgE-mediated (atopic) immune response in humans with a 
prevalence of IgE reactivity above 5%. However, although it does not carry any 
connotation of allergenic potency, an allergen is termed as being major if it is recognized 
by IgE in at least 50% of a cohort of allergic individuals sensitized to a given allergenic 
source; it is otherwise known as minor [7]. Please note that proteins are not the only 
molecules that can be an allergen. However, other types of allergens (antibiotics, metals, 
etc.) were not studied in the research. 
Interactions between IgE and allergens are crucial for allergic diseases, as the 
formation of an allergen-antibody complex is necessary for triggering an allergic reaction. 
The IgE-mediated allergic reaction requires an allergen to cross-link the IgE antibodies 
bound to the high-affinity receptors located on mast cells [8]. This cross-linking triggers a 
cascade of events leading to the degranulation of mast cells releasing proinflammatory 
mediators such as histamine. This results in allergic reaction symptoms in the skin, gastro-
intestinal tract, and respiratory system. These can include oral itching, lip swelling, labial 
edema, and even deadly reactions such as anaphylactic shock [8]. Retrospectively, 
understanding the chemical and physical interactions that occur between an allergen and 
an antibody is an indispensable tool in allergy diagnostics and therapeutics.  
Studying the allergen-antibody binding interface which comprises of the antigen 
binding site, epitope, and the antibody binding site, paratope, immensely contribute to 
understanding the molecular basis of allergy and allergic diseases.  However, studying 
allergen-antibody interactions is further complicated by IgE cross-reactivity between 
different allergens. Cross-reactivity occurs when the antibodies raised against one allergen, 




to the secondary protein [9].  Because IgE binding epitopes are conformational, they can 
experience substantial cross-reactivity with proteins of high sequence identity, especially 
on surface residues [10]. In nature, some allergens exist as isoallergens— allergens from a 
single species sharing similar molecular size, identical biological function and >67% amino 
acid sequence identity [7]. Additionally, the same allergen can be represented by several 
variants called isoforms. These isoforms typically have high sequence identity of more than 
97%. Due to high sequence homologies and three-dimensional structures, isoallergens and 
isoforms share extensive antigenic cross-reactivity [7].  
Although allergen extracts derived from natural sources are currently the main 
source of allergens used for allergy diagnosis and treatment, they contain other antigens 
and antigenic proteins which presumably might interfere with allergy treatment [11]. 
Additionally, the relative and absolute concentration of specific isoforms in individual 
extracts may differ. This is especially problematic as it has been shown that one isoform 
may be more antigenic than others, and that monoclonal antibodies raised against some 
potent allergens can sometimes discriminate between different isoforms [12,13]. 
Contrarily, recombinant allergens can provide not only standardized and known doses of 
allergens, [14] but, can also be easily modified to provide hypoallergenic variants having 
reduced IgE reactivity that may then be used in immunotherapy [11].  
It is hypothesized that characterization of molecular and antigenic properties of 
allergens is necessary for the development of better allergy diagnostics and therapeutics. 
The main mandate of this research was to study the structural, functional and 
immunological characteristics of HDM and profilin allergens for allergen specific 




antigenic surface of these allergens in contact with antibodies will facilitate allergy 
diagnostics and enable the design of hypo-allergens, with reduced IgE reactivity and 






STRUCTURAL, FUNCTIONAL AND IMMUNOLOGICAL STUDIES OF 
GROUP 1 AND 2 HOUSE DUST MITE ALLERGENS FOR EPITOPE 
RESOLVED ALLERGY DIAGNOSTICS AND IMMUNOTHERAPY1,2 
 
1.1 BACKGROUND AND INTRODUCTION TO HOUSE DUST MITE  
      ALLERGENS  
 
Dust mites are arthropods that thrive in warm areas of high humidity and feed on 
human skin flakes. In many households, dust mites are found almost everywhere including 
beds, carpets, and other furniture. Inhalation of HDM allergens, excreted in the mites’ fecal 
matter, is one of the most significant risk factors which leads to allergic diseases such as 
asthma, atopic dermatitis and rhinitis [15]. More than 22 million people in the USA alone 
who are exposed and sensitized to dust mites have developed asthma, a chronic 
inflammatory disease of the airways [16,17].  
__________________________________ 
1 Glesner J., Kapingidza A. B., Godzwon, M., Offermann L. R., Mueller, G. A., DeRose 
E. F., Wünschmann S., London R. E., Chapmann M. D., Ohlin M., Chruszcz M. and Pomés 
A. (2019). The Journal of Immunology 203 (9): 2545-255 
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Up to 85% of asthmatics are sensitized to house dust mites, and this number may 
exceed 90% in the tropics [18].  Globally, dust mite allergies occur in about 10-30% of the 
population [19]. In HDM allergy, IgE mediated immune response is elicited from two 
major dust mite species, Dermatophagoides farinae and Dermatophagoides pteronyssinus. 
These species are both sources of potent major allergens that stimulate IgE mediated 
immune response in more than 85% of sensitized individuals [20]. Although more than 35 
groups of dust mite allergens (Table 1.1) have been identified, Group 1 and 2 allergens 
have been found to be among the most important sources of potent allergens [20]. Studies 
have shown that Group 1 and 2 mite allergens combined bind 50–70% of the IgE that 
recognizes mite extracts [18]. Group 1 dust mite allergens (Der f 1 and Der p 1) are cysteine 
proteases whereas Group 2 (Der f 2 and Der p 2) belong to the Niemann Pick C2 (NPC2) 
family, which are proteins of approximately 130 amino acids that form a single β-sandwich 
domain [21]. 
 Group 1 mite allergens, Der f 1 and Der p 1, have 81% sequence identity while 
Group 2 allergens, Der f 2 and Der p 2, have 88% identical amino acids (Figure 1.2).  Due 
to this high sequence homology both Group 1 and 2 HDM allergens homologues exhibit 
significant IgE cross-reactivity. For example, Der p 2 was shown to have high risk of cross-
reactivity with its D. farinae homologue, Der f 2, and Eur m 2 (Euroglyphus maynei, 
originating from a European HDM and shares 83% sequence identity with Der p 2) [9]. 
Both Group 1 and 2 HDM allergens independently elicit IgE production in more than 80% 
of HDM allergic patients. Due to this high sensitization rate, the two groups are classified 




The allergenicity preeminence of Group 1 and 2 HDM allergens is attributed to the 
intricate mechanism these two groups of allergens interact with the human immune system. 
In retrospect, the proteolytic activity of Group 1 mite allergens has been proven to 
contribute to their allergenicity [22]. Group 1 mite allergens cleave CD23 and CD25 
receptors on mast cells, B-cells, T-cells and other immune cells involved in allergy immune 
response [21,23]. Cleavage of these receptors activates a cascade of events that lead to the 
release of proinflammatory cytokines by many immune cells including mast cells and 
basophils leading to a Th2 immune response. This results in the increase in IgE antibody 
production and inflammation of lung epithelium [24]. This helps explain why dust mite 
sensitization in very high among asthma patients. On the other hand, however, Group 2 
dust mite allergens show structural homology to and are mimickers of Lymphocyte antigen 
96, also known as MD-2, a lipopolysaccharide binding protein associated with Toll-like 
Receptor 4 (TLR-4) of the Toll-like receptor pathway. Due to this mimicry, Group 2 mite 
allergens can activate the innate immune system through TLR-4 resulting in a 95% 
prevalence of IgE antibodies response among asthmatics [25].   
The only available treatment for mite allergies consists of administering increasing 
doses of mite allergen extracts, which can cause adverse reactions to the patient (release of 
mediators such as histamine and inflammation) [26]. The primary objective of this research 
project was to produce hypo-allergenic molecules that have reduced reactivity to human 
IgE antibody for the development of better immunotherapy for HDM allergic patients. 
These hypo-allergens will decrease the adverse reactions presently observed in 




We hypothesized that molecular, structural, and immunological characterization 
of allergens in complex with antibodies is indispensable to the future of allergy diagnostics 
and immunotherapy.  To test this hypothesis, we studied Group 1 and 2 HDM allergens 
and their interactions with murine–derived IgG and/or human-derived IgE antibodies. The 
murine-derived antibodies used were known to interfere with IgE binding, hence their 
epitopes overlap [26].  In this case, IgG was used to study IgE binding because of its higher 
concentration in blood sera than IgE and increased propensity to crystallize [27].  
The research was carried out in three steps: 1) Expression, purification and 
characterization of recombinant allergens and IgE/IgG antibody fragments (the IgG were 
from mouse hybridomas and the IgE constructs were selected from combinational libraries 
designed from HDM allergic patients), 2) Identification of IgE/IgG epitopes on Group 1 
and 2 allergens by generating allergen-antibody complexes, and 3) Design and production 
of Group 1 and 2 HDM allergen mutants with reduced IgE binding affinity (Figure 1.3). 
Since most IgE epitopes are conformational, X-ray crystallography provides detailed three-
dimensional structural features of the IgE antibodies in complex with allergens, unveiling 
the important residues responsible for allergen-antibody interactions. Our previous 
research on Group 1 HDM allergens have proven that only a small number of residues 
within an epitope are functionally important for IgE antibody binding [28-30]. Hence, after 
the identification of these “hot-spots,” using site-directed mutagenesis, two double mutants 
on the 7A1epitope were generated. IgE binding affinities between the wild type natural 
and/or recombinant allergens and the mutants were compared using ELISA (enzyme-
linked immunosorbent assay). These allergen mutants with reduced IgE binding are good 




1.2 EXPRESSION AND PURIFICATION OF RECOMBINANT GROUP 1 AND 2  
      HDM ALLERGENS  
 
Over the years, several attempts were made to express Group 1 mite allergens in 
Escherichia coli (E. coli) or any other prokaryotic system without any success [31,32]. 
Hence, since Group 1 dust mite allergens, Der p 1 and Der f 1, require eukaryotic 
expression systems [33] these allergens were provided by our collaborators, Dr. Anna 
Pomés and her group at Indoor Biotechnologies (Charlottesville, VA). Two isoforms of 
Group 2 dust mite allergens Der p 2.0101 and Der p 2.0103 were cloned and expressed in 
E. coli and purified by Immobilized Metal Affinity Chromatography (IMAC) using Ni-
NTA (Nickel Nitrilotriacetic acid) and Size Exclusion Chromatography (SEC). Although 
Der p 2.0101 and Der p 2.0103 share 98% sequence identity (Figure 1.4A), producing 
different isoforms of Der p 2 was crucial because monoclonal antibodies raised against 
these Group 2 HDM allergens can sometimes discriminate between different isoforms 
[13,12]. 
Gene coding for Der p 2.0101 and additional N-terminal purification tag was 
synthesized and inserted into pJExpress411 plasmid (Kanamycin resistance) by DNA 2.0 
(currently ATUM, Newark, CA). The Der p 2.0101 insert was designed with a cleavable 
N-terminal cleavable purification His-tag MHHHHHHSSGVDLGTENLYFQ!SGSG, 
where the exclamation mark denotes the Tobacco Etch Virus (TEV) protease cleavage site. 
The plasmids were transformed into E. coli BL-21 (DE3) cells. One-liter Lysogeny Broth 
(LB) cultures were grown to an OD600 of 0.8 and induced with 500 µM isopropyl β-D-1-
thiogalactopyranoside (IPTG), cooled to 16°C, and grown overnight. Cell pellets were 
resuspended in lysis buffer (20 mM Tris-HCl, 500 mM NaCl, 2% glycerol, 10 mM 




9,000xg and a cell pellet was obtained. The supernatant was loaded onto a Bio-Rad Econo-
Pac chromatography column equilibrated with (50 mM Tris, 500 mM NaCl, 30 mM 
imidazole, 2% glycerol, pH 7.4) containing HisPur Ni-NTA resin. The protein was eluted 
using elution buffer (50 mM Tris-HCl, 50 mM NaCl, 250 mM imidazole, 2% glycerol, pH 
7.4).  
Elutions containing protein were determined by Sodium Dodecyl Sulphate-
Polyacrylamide Gel Electrophoresis (SDS-PAGE), then pooled and dialyzed overnight by 
using Pierce SnakeSkin Dialysis Tubing and dialysis buffer (50 mM Tris-HCl, 150 mM 
NaCl, pH 7.4). The dialyzed protein was concentrated using a Millipore Amicon Ultra 
concentrator with a 3,000 Da molecular mass cutoff and was further purified by SEC using 
a GE Healthcare ÄKTA-Pure FPLC and HiLoad Superdex 200 column. Fractions 
containing protein were concentrated as before and Der p 2.0101 concentration was 
determined by using a Thermo Scientific™ NanoDrop 2000 and purity by SDS-PAGE 
(Figure 1.4B). The protein was unstable and most of it precipitated or formed aggregates 
on the SEC column. The yield was 2.5 mg/L of culture.  
Attempts to cleave the N-terminal His-tag with TEV protease resulted in loss of 
significant amounts of protein. Therefore, a new construct without the purification tag was 
designed. The knockout construct did not express well in E. coli BL-21 (DE3). The 
instability of the Der p 2.0101 isoform both with and without the His-tag was thought to 
be caused by the misfolding of the protein. Der p 2 forms three disulfide bonds in its natural 
state which are important for its function [20]. The importance of these three disulfide 
bonds for protein folding and stability was confirmed previously [34]. Mutants of 




lacking the C21-C27 disulfide bond showed up to a 40-fold reduction in antibody binding 
and the mutant lacking C73-C78 disulfide bond showed more than a 100-fold reduction in 
IgE binding and failed to bind four antibodies [34]. Hence, these disulfide bonds play a 
crucial role in stabilizing the antigenic structure of Der p 2 and their presence in 
recombinant Der p 2 is required for proper folding. Therefore, it was reasoned that it was 
better to express the protein in a cell line that favors disulfide bond formation. Thus, the 
protein was expressed in E. coli T-7 Shuffle cells [35] using the same expression conditions 
mentioned above.  
The Der p 2.0101 protein without His-tag was purified by ion exchange 
chromatography using DEAE (diethylaminoethyl) column connected on ÄKTA Pure 
FPLC system (GE Healthcare). To remove excess salt from the ion exchange 
chromatography, the protein was dialyzed overnight in 50 mM Tris and 150 mM NaCl, pH 
7.4. The protein was then purified by SEC, but all of it precipitated on the column. Despite 
attempts to increase the protein yield and stability, the Der p 2.0101 isoform was unstable 
and degraded at 4°C in just one week. A later section will discuss how the instability of the 
Der p 2.0101 isoform was solved. 
For the Der p 2.0103 isoform, cloning, expression and purification conditions were 
changed substantially from those used for Der p 2.0101. DNA encoding for Der p 2.0103 
isoform was synthesized with an N-terminal cleavable His-tag just like the Der p 2.0101 
isoform and inserted into a kanamycin-resistant pET26b (+) plasmid by Bio Basic 
(Amherst, NY). The Der p 2.0103 gene was cloned in frame with a pelB leader sequence, 
a sequence of amino acids which when attached to a protein, directs the protein to the 




plasmid was co-transformed into E. coli BL-21 (DE3) strain together with protein disulfide 
isomerase 1, or PDI-1, plasmid (ampicillin resistance). PDI-1 is an enzyme located in the 
periplasm of bacteria and eukaryotes that catalyzes the breakage and formation of disulfide 
bonds between cysteine residues found within proteins as they fold [37]. Hence, PDI was 
used to aid disulfide bond formation in recombinant Der p 2 isoforms during expression in 
E. coli. 
One-liter terrific broth (TB) cultures were grown at 37°C to OD600 of 0.4 shaking 
at 200 rpm. The cultures were cooled to 22°C or room temperature, and grown to an OD600 
of 0.8-1.0 and then induced with 500 µM of IPTG, cooled to 16°C, and grown for 16–18 
hrs. Cell pellets obtained after centrifuging the overnight one-liter cultures were 
resuspended in lysis buffer (20 mM Na2HPO4, 500 mM NaCl, and 10 mM imidazole, pH 
7.4). After sonication, the cell lysate was centrifuged at 9000xg for 10 min at 4°C. The 
supernatant was purified by immobilized metal affinity using Ni-NTA. After loading the 
protein onto the column, the column was washed with wash buffer (20 mM Na2HPO4, 500 
mM NaCl, and 30 mM imidazole, pH 7.4). The protein was collected using elution buffer 
(20 mM Na2HPO4, 500 mM NaCl, and 300 mM imidazole and pH 7.4). The protein was 
further purified by SEC (Figure 1.5) in elution buffer. Protein purity was confirmed by 
SDS-PAGE. The final yield of the Der p 2.0103 isoform was 7 mg/L of culture. The 
obtained protein was used to set crystallization plates with Der p 2 specific antibodies. 
1.3 GENERATION, EXPRESSION AND PURIFICATION OF ALLERGEN  
      SPECIFIC ANTIBODIES AND ANTIBODY FRAGMENTS 
 
 To identify antibody binding epitopes for Group 1 and 2 dust mite allergens, 
allergen-antibody complexes were made. Using hybridoma technology our collaborators 




antibodies that had been isolated by Dr. Martin D. Chapman at the University of Virginia. 
Dr. Mats Ohlin, a collaborator in the NIH/NIAID R01 grant at Lund University, isolated 
IgE constructs from HDM allergic subjects using phage display technology which was later 
used by Dr. Anna Pomés’ group [26,29]. Hence, in this research, Dr. Anna Pomés and her 
group at Indoor Biotechnologies, provided us with whole IgE and IgG antibodies, as well 
as amino acid sequences encoding for the antibody variable domains specific for both 
Group 1 and 2 HDM allergens (Figure 1.3). Although whole IgE antibodies are the best 
candidates to be used in studying the interactions between Group 1 and 2 dust mite 
allergens and the human immune system, the amount of IgE antibodies that can be 
extracted from sera is very low [38,39]. Therefore, the ability to produce recombinant IgE 
and IgG antibody fragments like single-chain variable fragments (scFvs) and antibody 
fragments (Fabs) (Figures 1.6 and 1.7) selected from combinational libraries designed from 
HDM allergic patients (and sometimes mice) makes it possible to acquire significant 
amounts of recombinant allergen specific IgE and IgG antibodies suitable for use in X-ray 
crystallography and various other assays [26,28,40].  
The important part of an antibody are the variable regions which contain the antigen 
binding sites, called complementary determining regions (CDRs), (Figure 1.6) and because 
antibody fragments also possess these regions (Figure 1.7), they still have the same antigen 
specificity as full-length antibodies [27]. Antibody fragments also have other advantages 
over full length antibodies such as their ease of manufacturing and manipulating compared 
to full antibodies that are at least 150kDa [41]. Full antibodies are also too flexible for 
crystallization of allergen-antibody complexes for X-ray crystallography experiments. As 




whole IgE and IgG antibodies and often-times allergen-antibody complexes, for 
crystallization purposes, were made using intact full antibody. Although no one can predict 
the results of a crystallization experiment [42], it is an established fact that the flexibility 
of full antibodies considerably reduces the probability of a crystal forming [43]. To combat 
the flexibility, papain (or sometimes ficin) was used to cleave the crystallizable fragment 
(Fc) regions of IgG-derived antibodies to produce Fabs for use in crystallization 
experiments and other assays.  
1.4 PAPAIN PROTEOLYTIC CLEAVAGE OF FC REGIONS AND  
      PURIFICATION OF IGG MONOCLONAL ANTIBODIES 
 
 Papain proteolytic cleavage of whole IgG antibodies was used to obtain antibody 
fragments. Fabs of Group 1 and 2 specific IgG antibodies were cleaved and purified using 
the Pierce Fab preparation kit from Thermo Fisher as per the manufacturer’s protocol. 
Following cleavage of the whole antibody and purification of the Fab fragments, all 
experiments were conducted using just the Fab fragments. 
To prepare the allergen-antibody complexes, the allergen was mixed with the IgG 
Fab fragment in a 1:1 molar ratio and incubated at 4°C from one hour to overnight. After 
incubation, the solution was concentrated using an Amicon Ultra concentrator (Millipore) 
with a 10,000 Da molecular mass cutoff and purified by SEC on a Superdex 200 column 
attached to an ÄKTA Pure FPLC system (GE Healthcare).  A 20 mM Na2HPO4, 500 mM 
NaCl, 250 mM imidazole, and pH 7.4 buffer was used for SEC. (SEC was only conducted 
to test to see binding of allergen to antibody, but it was not always carried out). After SEC, 
fractions containing the Allergen-Fab complex were concentrated as mentioned above. The 





1.5 EXPRESSION AND PURIFICATION OF GROUP 1 HDM SPECIFIC  
      ANTIBODY FRAGMENTS 
 
 In this research, several full antibodies and antibody fragments specific to Group 1 
mite allergens were generated. Before the work presented in this manuscript was 
conducted, the Chruszcz’ lab had extensively characterized the structure of antigenic 
determinants of Group 1 HDM allergens in complex with antibodies and Dr. Pomés’ lab 
performed the mutagenesis and immunologic analysis of the epitopes [29,40,44]. However, 
most of the antibodies and antibody fragments used then were mainly monoclonal 
antibodies obtained from papain proteolytic cleavage of full antibodies, so there was need 
to attempt to produce recombinant versions of the same antibodies. In addition, some of 
the allergen specific antibodies such as the murine-derived mAb 6A8, specific to Der f 1, 
was not exhaustively characterized, and the crystal structure was not yet determined.  
Several antibodies in different formats specific to Group 1 HDM allergens were 
studied in this research (Table 1.2), and, as mentioned before, full mAb and Group 1 mite 
allergens were provided by our collaborators, Dr. Anna Pomés and her group at Indoor 
Biotechnologies. Fabs for recombinant antibody 4C1 and 1C14 (anti-Der p 1 antibody) 
were obtained using papain proteolytic as outlined above and the proteins were all used to 
set crystallization plates in complex either with Der p 1 or alone. However, IgG murine-
derived mAb 6A8 and Der f 1 specific antibody was the primary antibody worked on in 
this research. 
1.6 DER F 1 SPECIFIC MAB 6A8 CONSTRUCTS, EXPRESSION,  
      PURIFICATION AND CRYSTALLIZATION 
 
 Monoclonal antibody 6A8 has been widely used for decades both in commercial 




distinct from the epitope bound by the cross-reactive mAb 4C1 that binds both Der f 1 and 
Der p 1 [45]. Despite its extensive use, the crystal structure of mAb 6A8 has not been 
elucidated [30,45]. Furthermore, there is no literature that elaborates on the expression of 
this important antibody recombinantly. In the quest to crystallize mAb 6A8, milligram 
amounts of the antibody were needed. To meet this demand, after attaining the amino acid 
sequences that encode for the mAb 6A8 heavy and light chain regions from Dr. Anna 
Pomés and her group at Indoor Biotechnologies, antibody constructs in the form of scFvs 
were made.  
 The scFv format was chosen because the size of the antibody is considerably 
reduced to about 25 kDa which makes it easier for expression in E. coli and is also one of 
the simplest antibody formats to work with [46]. Single chain antibody fragments are made 
when the variable regions of light and heavy antibody chains encoding antigen-binding 
domains are engineered into a single polypeptide with a flexible linker comprising of only 
glycines and serines put in between the two regions. The glycines increase flexibility, and 
serines increase solubility [46,47] (Figure 1.7). At first, the 6A8 scFv was cloned, 
expressed and purified the same way as the Der p 2 isoforms mentioned above, however 
both the methods used failed. SDS-PAGE results showed no expression. Several E. coli 
strains including T-7 Shuffle cells and changing growth conditions yielded no amount of 
detectable protein. However, a literature search revealed that some proteins can be toxic to 
E. coli leading to little or no expression of such proteins. Fortunately, the C41 E. coli cell 
line was developed for such proteins and was available in the lab [48].  
 Gene coding for 6A8 scFv and an additional non-cleavable C-terminal purification 




resistance) by Bio Basic (Amherst, NY). The plasmid was transformed into E. coli C41 
cells. One-liter TB cultures supplemented with kanamycin were grown to OD600 of 0.4 at 
37°C and then the temperature was lowered to room temperature. The cultures were shaken 
until OD600 of 1.0-1.2 then induced with 500 µM IPTG, cooled to 16°C, and grown 
overnight. Cell pellets were resuspended in lysis buffer (50 mM Tris-HCl, 500 mM NaCl, 
2% glycerol, 10 mM imidazole, pH 7.4) and lysed by sonication. The sonicated mixture 
was centrifuged at 9, 000xg to obtain a cell pellet. The supernatant was loaded onto a Bio-
Rad Econo-Pac chromatography column equilibrated with (50 mM Tris, 500 mM NaCl, 30 
mM imidazole, 2% glycerol and pH 7.4) containing HisPur Ni-NTA resin. The protein was 
eluted using elution buffer (50 mM Tris-HCl, 50 mM NaCl, 250 mM imidazole, 2% 
glycerol, pH 7.4). SDS-PAGE showed that expression of 6A8 scFv had been considerably 
enhanced (Figure 1.9). 
Elutions containing protein were determined by SDS-PAGE pooled and 
concentrated using a Millipore Amicon Ultra concentrator with a 3,000 Da molecular mass 
cutoff. The scFv was further purified by SEC using a GE Healthcare ÄKTA-Pure FPLC 
and HiLoad Superdex 200 column. Elution buffer was used for SEC. The protein was 
unstable and most of it precipitated and/or aggregated on the SEC column. The yield was 
approximately 1.5mg/L of culture or less. The 6A8 scFv instability was such that the 
protein would degrade at 4ºC after just 4 days. To test the binding affinity of the scFv to 
natural Der f 1 (nDer f 1), this unstable protein was sent to Dr. Anna Pomés and her group 
at Indoor Biotechnologies for ELISA (Enzyme-Linked Immunosorbent Assay) 




 It was reasoned that the instability of the scFv might have been caused by 
misfolding of the protein. This was a credible rationale because research has demonstrated 
that in the design of the scFv antibody construct the length of the linker plays a crucial role 
in the folding of the protein. Too long of a linker could lead to over-flexibility of the scFv 
resulting in misfolding and instability of the protein [49]. The first 6A8 scFv construct had 
a linker comprising of 15 amino acid residues (GGGGS)3; hence we reduced the linker 
length to 10 amino acids (GGGGS)2 (Figure 1.8). Despite these changes, 6A8 scFv was 
still unstable.  
 Although expressing mAb 6A8 in the scFv format was tested thoroughly, the results 
acquired were somewhat expected because scFv antibody fragments are notoriously known 
for their instability and low expression in E. coli expression systems [50]. Retrospectively, 
we changed the format of the antibody to Fabs. The difference between an scFv and a Fab 
is that the Fab contains constant regions and is connected by a disulfide bridge (Figure 1.7). 
This can make a considerable difference in the stability and sometimes even increase the 
affinity of the antibody to its antigen [51] (Figure 1.8). Gene coding for the light chain 
variable and constant regions with a C-terminal non-cleavable His-tag were cloned into a 
pET22b (+) plasmid with the heavy chain being cloned into a pET26b (+) plasmid by Bio 
Basic (Amherst, NY). The plasmids were co-transformed into C41 cells and the same 
expression and purification conditions explained above for the 6A8 scFv were used. SDS-
PAGE confirmed the expression of both the light and heavy chain in considerable amounts. 
However, the light chain was more abundant than the heavy chain (Figure 1.10). After 
SEC, the light chain had a final yield of 6-8 mg/L of culture. The protein was significantly 




made before. Crystallization plates were set using thousands of crystallization conditions. 
Fortunately, the protein crystallized within a couple of weeks, but upon determination of 
the crystal structure, it was found that the crystallized protein was a 6A8 light chain dimer, 
not a Fab. Despite several attempts made to also over-express mAb 6A8 heavy chain and 
crystallize the antibody as a Fab, only crystals of the light chain dimers were obtained 
(Figure 1.11) 
1.7 CRYSTALLIZATION, DATA COLLECTION AND STRUCTURE             
      DETERMINATION OF 6A8 LIGHT CHAIN DIMER 
 
Crystallization of the 6A8 light chain dimer was performed at 277 K. The best 
diffracting crystals were grown using the sitting drop vapor diffusion method. The crystals 
were obtained when 5 mg/mL protein sample was mixed in a 1:1 volume ratio with well 
solution composed of 0.2 M ammonium sulfate, 0.1 M Bis-Tris at pH 5.5, and 25% w/v 
polyethylene glycol 3,350. Data collection for the 6A8 light chain dimer was performed 
remotely using the Southeast Regional Collaborative Access Team (SER-CAT) 22-ID 
beamline at the Advanced Photon Source (APS), Argonne National Laboratory (Lemont, 
IL).  
Data were processed with HKL-3000 [52] and structure was determined using 
MOLREP [53] incorporated into HKL-3000 and molecular replacement method. PDB 
structure 3RVU was used as a search model. The model was rebuilt with Buccaneer [54] 
and ARP/wARP [55]. Model refinement was performed using REFMAC [56] and HKL-
3000. Some programs from the CCP4 package [57] were used for data handling. The model 
was manually adjusted using COOT [58]. COOT and MOLPROBITY [59] were used for 





1.8 MAB 6A8 LIGHT CHAIN DIMER STRUCTURE ANALYSIS 
 The 6A8 light chain dimer X-ray crystal structure was determined in the C222 space 
group at 2.80 Å resolution with one dimer in the asymmetric unit (Table 1.3). One chain is 
comprised of two β-sandwich motifs as is common of most of light chain dimers in the 
PDB [61] (Figure 1.12). The β-sandwich of the constant region is comprised of seven 
antiparallel β-strands bounded by α-helices on the side opposite the variable region. The β-
sandwich of the variable region is comprised of ten antiparallel β-strands bounded by one 
α-helix on the same side as the constant region (Figure 1.11). The three CDRs, as predicted 
by the Paratome server [62], protrude from the β-sandwich allowing for binding of the 
antigen (Figures 1.11 and 1.13A). As is common with most antibodies, the 6A8 light chain 
dimer contains two disulfide bonds, one between C24 and C88 in the variable region and the 
other between C135 and C195. Both disulfide bonds are buried in the middle of their 
respective β-sandwich. 
 B-factors, also called displacement parameters, can be used to describe the relative 
mobility of various atoms in the crystal structure. Atoms with higher B-factors values are 
located in fragments of molecules that display a higher mobility/disorder. Figure 1.13B 
shows the distribution of B-factors for the 6A8 light chain dimer. Overall, the variable 
regions have lower B-factors compared to the constant regions. Constant regions have the 
highest mobility/displacement of residues as denoted by the red color and the larger 
diameter of ribbons. Such distribution of B-factor values can be explained by the fact that 
the constant domains form less crystal contacts and are more exposed to the solvent. 
Contrarily, the variable domains are involved in more interactions with neighboring 




This is represented by lower B-factor values (shown by the blue color and the smallest 
ribbon diameter; Figure 1.13B). 
 There are two interfaces that are responsible for the light chain dimer formation. 
One of the interfaces is formed by the constant regions and the other by the variable 
regions. PDBePISA [63] analysis indicates the interface between the two chains is 
comprised of approximately 44 residues from each chain covering an area of about 
1,200Å2. The dimer is stabilized by various hydrophobic interactions, as well as hydrogen 
bonding (Table 1.5). The following residues, however, contribute the most area to the 
interactions on the dimer interface: N35, L37, Q39, I45, R47, D56, Y88, L90, P96, W97, F99, G100, 
F119, V134, F136, S163 and T165. Despite the structure being a homodimer, the chain 
conformation is not identical. For example, Asp168 and Ser177 from chain B contribute 
towards hydrophobic interactions in the interface, but both these residues from chain A do 
not contribute to the interface interactions. 
1.9 OTHER ANTIBODY FRAGMENT CONSTRUCTS MADE FOR MAB 6A8 
 In the quest to obtain a Fab for mAb 6A8, other constructs were made. (All the 
expression plasmids used hereafter were also cloned by Bio Basic (Amherst, NY). The 
same expression and purification methods used for the scFv were employed for all the other 
mAb 6A8 antibody formats). To start with, we employed a multi-gene expression system, 
the pETDuet-1 plasmid, that enables expression of two proteins using one plasmid [64]. 
By using this system, it was reasoned that both the heavy and light chain would be 
expressed in equimolar amounts. The heavy chain and light chain were expected to make 
a complex in vivo, therefore the C-terminal histag was eliminated from the light chain 




chain, and the light chain neither bound to the heavy chain in vivo nor was obtained in flow 
through during Ni-NTA. However, the heavy chain was unstable and precipitated on the 
SEC column. Attempts were made to complex the heavy chain and the light chain (obtained 
from the light chain expressed alone), but the heavy chain still precipitated on the SEC 
column to obtain just the light chain.  
Finally, drastic measures were implemented to coerce the two antibody chains to 
make a complex, so fusion proteins with glutathione S-transferase (GST) were made. GST 
is commonly used as a fusion protein to increase the stability and solubility of the protein 
it is fused to [65]. However, GST also possesses another quality found in its propensity to 
form dimers (Figure 1.8) [66]. At first, the heavy and light chain GST-fusion proteins were 
co-expressed in C41 cells but co-expression of the two chains resulted in over-expression 
of the heavy chain GST-fusion protein. This too was unstable and precipitated on the SEC 
column. Afterwards, the two fusion proteins were expressed in C41 E. coli cells 
individually. Because the light chain GST-fusion protein lacked the C-terminal His-tag, the 
protein was purified using GST column following protocols described previously [65]. The 
SDS-PAGE run after purification showed low expression of the light chain GST-fusion 
protein compared to the heavy chain. The two proteins were mixed together and run on 
SEC column. They both precipitated on the column and no complex was observed. Since, 
all attempts employed to obtain mAb 6A8 in a stable Fab format were unsuccessful, all 
experiments done thereafter were performed using the light chain dimer. In hindsight, it is 
important to note that the instability of the GST-fusion proteins might have been attributed 






1.10 ELISA EXPERIMENTS: SPECIFICITY AND BINDING AFFINITIES OF  
        MAB 6A8 LIGHT CHAIN DIMER 
 After an arduous three years of trying to obtain a Fab for mAb 6A8, a thorough 
review of literature reinvigorated the idea that light chain dimers were not as peculiar in 
human health and surprisingly, in allergy [67]. Research showed that in the human body, 
light chains are usually more abundant than heavy chains and the formation of light chain 
dimers is associated with several auto-immune diseases including rhinitis [68,69].  Hence, 
further experiments to investigate the binding affinity and specificity of mAb 6A8 light 
chain dimer were warranted. ELISA experiments were carried out by our collaborators, Dr. 
Anna Pomés and her group at Indoor Biotechnologies, to check the binding of mAb 6A8 
light chain dimer (produced in this research) to Der f 1 and other allergens that exhibit high 
cross-reactivity to Der f 1. Indeed, as expected, the light chain dimer could bind to Der f 1. 
Conversely though, full mAb 6A8 is known to be specific to Der f 1, but the light chain 
dimer did not only bind to Der p 1, but also to Der p 2.0103. To confirm and reiterate the 
same results that Dr. Anna Pomés and her group had acquired, 6A8 light chain dimer was 
mixed in the ratio 1:1 with Der p 2.0103 and incubated overnight at 4°C. To check the 
formation of a 6A8 light chain dimer-Der p 2.0103 complex, the sample was purified by 
SEC in this buffer (50 mM Tris-HCl, 50 mM NaCl, 250 mM imidazole, 2% glycerol, pH 
7.4). Although not all the Der p 2.0103 bound to the 6A8 light chain dimer, some amount 
of the Group 2 allergen was bound as confirmed by SDS-PAGE. This shows that the 
affinity of the dimer to Der p 2.0103 is lower than the nanomolar range expected for an 
antibody (Figure 1.14).  
 The binding of 6A8 light chain dimer to Der p 2, although a surprising result, 




the difficulty we were having of co-crystallizing the dimer with an allergen. To test 6A8 
light chain dimer specificity to HDM allergens, our collaborators, Dr. Anna Pomés and her 
group at Indoor Biotechnologies, performed further ELISA experiments with allergens 
from various sources including cat, peanuts, cockroach, and gamma globulin (Figure 1.15). 
These results irrefutably confirmed that 6A8 light chain dimer will bind to almost anything, 
not just the mite allergens, and it is non-specific. 
1.11 PRODUCTION, EXPRESSION AND PURIFICATION OF GROUP 2 HDM   
        SPECIFIC ANTIBODY FRAGMENTS 
As mentioned before, using hybridoma technology our collaborators at Indoor 
Biotechnologies generated Group 2 HDM specific murine monoclonal antibodies that had 
been isolated by Dr. Martin D. Chapman at the University of Virginia. Hence, Dr. Anna 
Pomés and her group provided us with full IgG antibodies as well as amino acid sequences 
encoding for the antibody variable domains specific for Group 2 HDM allergens. Three 
murine-derived IgG monoclonal antibodies specific to Der p 2 were generated in this 
research namely 7A1, 1D8 and αDPX. Despite many attempts done (including changing 
antibody formats to Fabs) to express and purify mAb 1D8 and αDPX, the antibodies 
expressed poorly and were unstable. Although many crystallization plates were set up, no 
diffracting quality crystals were obtained for αDPX. It’s only recently after more than 1.5 
years when one 1D8 scFv crystal diffracted, albeit poorly. Hence, no further experiments 
could be carried out with the two antibodies. Conversely, one of the three antibodies, mAb 
7A1, although difficult to express and purify at first, gave good results and was extensively 







1.12 PRODUCTION, CRYSTALLIZATION AND STRUCTURE            
        DETERMINATION OF MAB 7A1 FAB 
 
Full IgG mAb 7A1 was received from Dr. Anna Pomés and her group at Indoor 
Biotechnologies, and Fabs were generated by papain proteolytic cleavage of the Fc regions 
as described above. The resulting Fab were purified using a Pierce Fab Preparation Kit 
(Thermo Fisher Scientific, Grand Island, NY) according to the manufacturer’s protocol. 
Allergen-antibody complex was prepared by mixing the Fab fragment in a 1:1 molar ratio 
with Der p 2.0103 and incubating at 4°C for 30 min. After incubation, the complex was 
concentrated, purified by SEC on a Superdex 200 column using 10 mM Tris-HCl, 150 mM 
NaCl, and pH 7.4 buffer. Fractions eluted from the SEC column containing Der p 2.0103 
in complex with Fab from mAb 7A1 (Der p 2.0103–7A1 Fab) were pooled, concentrated 
to 5 mg/mL, and used for crystallization.  
Crystallization of the Der p 2.0103–7A1 Fab was performed at 298 K using the 
sitting drop vapor diffusion method. The protein complex was mixed at a 1:1 ratio with 
each crystallization condition. Crystallization conditions that yielded crystals of diffraction 
quality contained 100 mM Bis-Tris, 200 mM ammonium acetate, and 30–55% 2-methyl-
2,4-pentanediol (pH 6.5) (well solution). Der p 2.0103-7A1Fab crystals were cryo- 
protected using well solution, then immediately cooled in liquid nitrogen. Data was 
collected at the Southeast Regional Collaborative Access Team 22-ID at the Photon 
Advanced Source, Argonne National Laboratory (Lemont, IL). Diffraction images were 
processed using HKL-3000 [52]. Summary for data collection statistics is presented in 
Table 1.4. The structure was determined using molecular replacement with PDB structures 
1KTJ (Der p 2) and 3RVT (Fab) as starting models. The interpretation of the electron 




the antibody described above. HKL-3000, MOLREP [53], and selected programs from the 
CCP4 package [57] were used for structure determination. The model was rebuilt using 
Buccaneer [54] and COOT [58], refined using REFMAC [56] and COOT, and validated 
using MOLPROBITY [59]. The final model together with structure factors were deposited 
to the PDB with accession code 6OY4.  
1.13 CRYSTAL STRUCTURE OF DER P 2.0103–7A1 FAB COMPLEX 
 The structure of Der p 2.0103–7A1Fab was determined at 2.45Å resolution (Table 
1.4). The complex crystallized in the C2 space group with one complex copy per 
asymmetric unit. The epitope has an area of ∼750 Å2, and 64% of this area corresponds to 
a region that interacts with the variable fragment of the antibody heavy chain (Figure 
1.16B). Most of the hydrogen-bond interactions between residues forming the epitope and 
the paratope are formed by two fragments of Der p 2.0103 (Arg31-Gly32-Lys33-Pro34 and 
Lys96-Ile97) that interact mostly with amino acids from CDR2 and CDR3 of the heavy chain 
(H) and a residue from CDR3 from light chain (L) (L CDR3) (Figure 1.16C). Direct 
contacts between allergen and antibody are not only mediated by hydrogen-bonds, but there 
are several residues, such as Pro34, Pro95, Ile97, and Pro99 that participate in hydrophobic 
interactions. In addition, there is a cation-pi interaction involving Lys96 (Der p 2.0103) and 
Trp50 (H CDR2) with the ∼3.5 Å distance between the interacting side chains (Figure 
1.16C). The structural analysis shows that Lys33 and Pro34 are responsible for a significant 
fraction of the epitope area that is in contact with the L chain of mAb 7A1, whereas Lys96 
and Ile97 play a similar role in the contact with the H chain. Ile97 is wedged against CDR2, 
CDR1, and indirectly against CDR3, but in the last case, the interaction is mediated by a 




but also by indirect contacts through water molecules. In fact, the crystal structure revealed 
11 water molecules (Figure 1.16B, 1.16C) that were trapped between the allergen and 
antibody and participate in mediating contacts between these two molecules. 
1.14 CONFORMATIONAL CHANGES UPON MAB 7A1 FAB BINDING TO  
        DER P 2.0103 BY X-RAY CRYSTALLOGRAPHY 
 
 In the crystal structure of the Der p 2.0103–7A1Fab, the majority of the symmetry-
related contacts are formed by the Fab fragment. Consequently, the structure provided an 
opportunity to compare the conformation of the antibody bound Der p 2.0103 with the 
conformation of the free allergen (Der p 2.0101; 1KTJ). The binding of mAb 7A1 Fab 
induced several localized perturbations to Der p 2.0103, with notable regions including the 
Glu62-Gly67 fragment (Figure 1.17A–C, small oval), along with a discontinuous sequence 
of the allergen that is distal from the epitope (Figure 1.17A–C, large oval). In the former, 
residues 63 and 64 showed the greatest variation, with displacement distances of 2.3Å and 
3.8Å, respectively, between the two structures (Figure 1.17E; amplified view of the small 
oval in Figure 1.17C). Interestingly, despite the proximity of the epitope to the 
aforementioned residues, the actual epitope region experienced significantly reduced 
conformational changes relative to this region (Figure 1.17F). The distal (big oval) region 
encompassed a larger number of residues, potentially contributing to the increased disorder 
of the region, particularly in the vicinity of the Cys73-Cys78 disulfide bridge. 
1.15 PRODUCTION, EXPRESSION AND PURIFICATION OF MAB 7A1 scFv 
 Although a crystal structure of mAb 7A1 in complex with Der p 2.0103 had been 
obtained, more protein was needed for further experiments to characterize the 
immunological and molecular characteristics of mAb 7A1. After obtaining the DNA 




and her group at Indoor Biotechnologies, the gene insert for the 7A1 scFv with a C-terminal 
poly-histidine purification tag was cloned into the ampicillin-resistant pET21b (+) plasmid 
(Bio Basic, Amherst, NY). The plasmid was co-transformed into E. coli BL-21 (DE3) 
strain together with the pKJE7 (chloramphenicol resistance) plasmid that encodes for 
chaperones DnaK, DnaJ, and GrpE (Takara Bio, Mountain View, CA). Plasmid cultures (1 
L of Lysogeny Broth) were grown at 37°C to OD600 of 0.8, after which the cultures were 
cooled to 22°C or room temperature, and were induced with 0.4 mM of IPTG, cooled to 
16°C, and grown for 16–18 hrs. Cell pellets obtained after centrifuging the overnight 1 l 
cultures were resuspended in lysis buffer (20 mM Na2HPO4, 500 mM NaCl, 10 mM 
imidazole, and pH 7.4). After sonication, the cell lysate was centrifuged at 9000xg for 10 
min at 4°C. The supernatant was purified by immobilized metal affinity using Ni-NTA. 
After loading the protein onto the column, the column was washed with wash buffer (20 
mM Na2HPO4, 500 mM NaCl, 30 mM imidazole, and pH 7.4). The protein was eluted 
using elution buffer (20 mM Na2HPO4, 500 mM NaCl, 250 mM imidazole, and pH 7.4). 
7A1 scFv protein was further purified by SEC in elution buffer. After SEC, samples 
containing the protein were dialyzed in buffer containing 20 mM Na2HPO4, 150 mM NaCl, 
and 100 mM EDTA at pH 7.4. The yield was 10 mg/L culture. The protein was used for 
crystallization experiments and some of it was sent to our collaborators, Dr. Mueller and 
his group, at the National Institute of Environmental Health Sciences (NIEHS) for 
structural studies using NMR. 
 The purification and expression of 7A1 scFv proved difficult at first even when 
various cell lines were used.  Finally, BL-21 (DE3) E. coli strain along with the pKJE7 




protein stability and solubility, several buffer systems were tried.  A comparison of Tris 
and Potassium Phosphate buffers are shown in (Figure 1.18).  The yield of 7A1 scFv 
drastically increased from ~1 mg/L of bacterial culture to ~7-9 mg/L when sodium 
phosphate buffers were used instead of Tris.  The stability of the antibody was also 
significantly enhanced as the protein did not degrade for 6 weeks at 4°C. 7A1 scFv would 
also highly precipitate in the absence of imidazole and during freeze-thaw cycles, but the 
addition of 100mM EDTA solved the problem. Although this was a great achievement, the 
antibody was still considerably unstable as evidenced by the aggregates obtained during 
the SEC. To troubleshoot this problem, literature review on improving the stability of 
antibody fragments highlighted that co-expression of the antibody with its specific antigen 
significantly increases not only the stability, but also the expression of both the allergen 
and the antibody [70]. Co-expression of 7A1 scFv with Der p 2 isoforms would 
simultaneously solve two problems.  Please call to mind that isoform Der p 2.0101 was 
also very unstable and exhibited poor expression.  
1.16 CO-EXPRESSION AND PURIFICATION OF MAB 7A1 SCFV WITH  
        DER P 2.0101 
The same expression and purification methods as mentioned above for the 
production of 7A1 scFv alone were used for the expression and purification of the 
7A1scFv-Der p 2.0101 complex. The SDS-PAGE after IMAC (Figure 1.19A) suggested 
the allergen and antibody were expressed in 1:1 ratio.  Co-expression of 7A1 scFv and Der 
p 2.0101 reduced protein aggregation and increased stability, as evidenced by the SEC 
chromatogram in (Figure 1.19B).  After SEC, the yield of the 7A1-scFv and Der p 2.0101 
complex (44.52kDa) was 10 mg/L of culture, and the single peak obtained in the elution 




complex. 7A1 scFv was also co-expressed with Der p 2.0103 isoform and the same results 
obtained for Der p 2.0101 were observed.  
1.17 CONFORMATIONAL CHANGES BY NMR IN DER P 2 UPON   
        COMPLEXATION WITH MAB 7A1 SCFV 
 
The crystal structure obtained from the 7A1 Fab-Der p 2.0103 complex suggested 
that binding of mAb 7A1 significantly altered Der p 2 structure and dynamics, particularly 
in the region distal from the epitope site discussed above. To further explore this 
possibility, our collaborators, Dr. Mueller and his group at NIEHS, studied the complex of 
mAb 7A1 scFv with Der p 2.0101 in solution using Heteronuclear Multiple Quantum 
Coherence (HMQC) NMR. They generated complexes of mAb 7A1 scFv (produced in this 
research) with an excess of methyl labeled Der p 2.0101. 1H-13C-NMR was used to monitor 
conformational changes in 13C-methyl labeled Ile, Leu, Val side chains, a labeling scheme 
which is particularly suited to maintain high sensitivity even in high molecular weight 
systems [71].  
Chemical shift perturbations were observed for Ile28, Leu61, Val63, and Val116, along 
with a significant reduction in NMR signal intensity of Ile97 upon formation of the mAb 
7A1 complex. The reduction in intensity of Ile97 are attributed to conformational exchange 
upon binding. These findings were consistent with the crystal structures, in which all the 
aforementioned residues that show shift changes in the NMR spectrum display 
conformation changes upon mAb 7A1 Fab binding (Figure 1.17C, 1.17D). Additionally, 
the slight shift in the peak for Val116 1H-13C mirrors the distal conformational changes 
shown in Figure 1.17A, 1.17C, further validating the structural rearrangements observed 





1.18 EPITOPE ANALYSIS FOR RATIONAL DESIGN OF MAB 7A1 EPITOPE    
        MUTANTS 
 
The ultimate goal of this research was to design Group 2 HDM allergen mutants 
with reduced IgE binding that could be exploited in HDM allergy immunotherapy. To 
achieve this goal, amino acid residues critical for IgE binding had to be identified by 
studying the allergen-antibody interactions on the epitope-paratope interface. The crystal 
structure of the Der p 2.0103–7A1 Fab complex along with the 1H-13C-NMR studies 
allowed for the identification of several allergen residues that are critical for interaction 
with the antibody. Based on these insights, two double mutants (Arg31Ala-Lys33 Ala and 
Lys96Glu-Ile97Glu) of the allergen were designed to decrease their ability to bind mAb 7A1.  
The first set of mutations was designed to affect the interaction with the L chain 
(Arg31Ala-Lys33Ala) through replacing long and positively charged side chains with 
methyl groups to reduce the number of H-bonds in the epitope-paratope interface. Arg31 is 
responsible for a strong interaction with Glu57 from H CDR2, whereas Lys33 participates 
in formation of two hydrogen bonds with Ser95 from L CDR3 and Asp104 from CDR3 from 
H chain (H CDR3). Therefore, mutation of these two residues to alanine was expected to 
completely abolish their ability to form the network of H-bonds that involved their side 
chains (Figure 1.16C).  
The second set of mutations (Lys96Glu-Ile97Glu) targeted the interaction with the H 
chain. In this study, a stretch of residues (Val94-Pro99) was identified in the structure that 
lined the complex interface and might therefore play a role in antibody binding, from which 
Lys96 and Ile97 were selected to be substituted (Figure 1.16C). Lys96 forms a hydrogen bond 
through the Phe102 (H CDR3) main chain oxygen atom and is also involved in interactions 




bound through hydrogen bonds with two neighboring water molecules, as well as with 
Asp98 (L CDR3). Moreover, Lys96 is close (3.7 Å) to the carboxyl group of Asp104 (H 
CDR3).  
Substitution to Glu at position 96 was expected to perturb this hydrogen bond 
network while also giving rise to unfavorable electrostatic repulsion with the negatively 
charged carboxylate groups. Ile97 also forms a hydrogen bond through main chain atoms 
with amide group of Asn52, which is not expected to be affected by the mutation (H CDR2) 
and, in addition, interacts through the side chain and hydrophobic interactions with Asn31 
(CDR1 from H chain) and Tyr54 (H CDR2). The Ile97Glu mutation also eliminated the large 
aliphatic side chain of Ile97 that was wedged against CDR1 from H chain and H CDR2 and 
was expected to significantly reduce the ability of this residue to form extensive 
hydrophobic contacts. In summary, the mutation did not only result in substitution of a 
hydrophobic amino acid with a hydrophilic residue, but also changed the charge from 
neutral to negative. 
Furthermore, according to the so-called hotspot hypothesis, only a few very specific 
residues on the antigen–antibody interface within each paratope and epitope are critical for 
antigen recognition and binding [34]. Site directed mutagenesis on epitope residues have 
supported this hypothesis. Mutations of one, two, or three epitope residues significantly 
reduced, or even abrogated antibody binding showing that only a few residues dominated 
the energetics of the antigen–antibody interactions [26,29]. Reduction of antibody binding 
is usually encompassed by a reduction in antibody binding affinity as measured by the KD 
(the equilibrium dissociation constant between the antibody and its antigen) [29]. Our 




binding by 10-1,000 fold (from nano-molar to micro-molar KD values) depending on the 
number of mutations done and on the importance of the mutated residue for antibody 
binding. However, generally, we observed an exponential decrease/increase of KD values 
with each subsequent mutation [29]. Henceforth, all the mutations done for mAb 7A1 were 
expected to show a reduction in IgE binding as demonstrated by a reduction in KD values 
[26, 29].                                               
1.19 SITE-DIRECTED MUTAGENESIS OF THE mAb 7A1 EPITOPE ON DER P 2  
        AND EFFECT OF EPITOPE MUTATIONS ON mAb 7A1 BINDING 
 
Our collaborators, Dr. Anna Pomés and her group at Indoor Biotechnologies, 
generated the Der p 2 mutants, evaluated the IgE binding affinities of the mutants and 
compared them to the wild type allergen. Site-directed mutagenesis of the mAb 7A1 
epitope on Der p 2 was performed using the QuickChange Site-Directed Mutagenesis Kit 
(Agilent Technologies, Santa Clara, CA). Recombinant Der p 2.0103 wild type and 
mutants were expressed in a methanol-inducible Pichia pastoris system and purified over 
an mAb 7A1 or 1D8 affinity chromatography column, respectively. The allergens were 
eluted with 0.1 M glycine and 0.15 M NaCl (pH 2.5) and concentrated and dialyzed in PBS 
(Phosphate-Buffered Saline). 
To evaluate IgE binding capabilities of Der p 2 mutants, direct binding of mAbs 
7A1 and 1D8 to Der p 2 wild type and mutants was assessed using a direct antibody binding 
immunoassay.  The capacity of the two Der p 2 mutants to bind the mAb 7A1 was 
completely abolished by the amino acid substitutions discussed previously as shown by 
direct and inhibition binding assays (Figure 1.20). However, the ability of mAb 1D8 
(whose epitope lies opposite from the mAb 7A1 epitope) to bind the mutants was preserved 




folding of the mutants versus the wild type was confirmed by NMR (1D-NOESY) 
performed by Dr. Mueller and his group. These results confirmed that the Der p 2 mutants 
were properly folded and the reduction in IgE binding was due to the mutations, and not 
improper folding of the protein.  
IgE binding of the Der p 2 mutants compared with wild type was also tested using 
patient blood plasma. IgE inhibition experiments were carried out by Dr. Anna Pomés and 
her group at Indoor Biotechnologies; using plasma from five different patients acquired 
from PlasmaLab International (Everett, WA), which operates in full compliance with Food 
and Drug Administration regulations. Informed donor consent was obtained from each 
individual prior to the first donation. The differences in the ability to inhibit plasma IgE 
antibody binding to wild type Der p 2 between mutants and wild type were from 10-fold 
up to 100-fold among the five patients. The data obtained from patient inhibition assays 
confirmed a consistent decrease in IgE binding to the mutants versus the wild type (Figure 
1.20B). Given that the human IgE antibody response is polyclonal, the mutations 
performed were not expected to completely inhibit plasma IgE antibody binding, but only 
affect the binding of those IgE that recognize a site overlapping with the mAb 7A1 epitope. 
This decrease of IgE binding to the mutants could reflect partial or complete abolition of 
binding of those IgE antibodies that overlap with mAb 7A1. 
1.20 DISCUSSION 
 Allergens, supposedly harmless substances to most people, pose a major health 
threat to more than one third of the world’s population [1].  These allergens stem from 
various sources including pollens, food and other aeroallergens.  To exacerbate the 




similar allergens giving rise to conditions such as pollen-food syndrome [10].  Allergies 
are not only a nuisance, but an aggravator of conditions exemplified in asthma, atopic 
dermatitis, and allergic rhinitis [15,17]. HDM allergens in particular, have been shown to 
either exacerbate symptoms in asthmatic patients, or act as a trigger to the development of 
asthma, atopic dermatitis and rhinitis.  Up to 85% of atopic asthmatics are allergic to HDM 
allergens in some regions [20]. Among major allergens from HDM, Group 1 and 2 
allergens are recognized by IgE by more than 80% of sensitized individuals [20]. Studies 
show that Group 1 and 2 mite allergens combined bind 50–70% of the IgE that recognizes 
mite extracts [18]. Structural analysis of the IgE recognition of allergens is the basis for 
rational design of recombinant counterparts to be used in the future for immunotherapy. 
 Previous studies by our group reported the structures of Group 1 HDM allergens, 
Der p 1 and Der f 1, in complex with Fab of murine IgG mAbs [72-75]. These IgG mAbs 
were used as surrogates for IgE antibodies because 1) they were reported to inhibit IgE Ab 
binding to the allergen, which confirmed their epitope overlap with IgE binding site(s), and 
2) they are homogeneous proteins, which is needed for crystallization purposes (unlike 
serum IgE that is not possible to crystallize because of its polyclonal nature). This approach 
allowed the determination of IgE antibody binding sites by detailed site-directed 
mutagenesis analysis of the IgG epitope.  
 The recurrent crystallization of the 6A8 light chain dimer instead of a Fab, although 
a surprising and quite disappointing result, emerging research suggest light chain dimer 
formation is not as peculiar in human health and allergic diseases like asthma and rhinitis 
[67].  In a normal setting, allergic rhinitis and asthma are deemed to share a unified disease 




lead to the production of allergen specific IgE antibodies from activated B cell-derived 
plasma cells. In retrospect, patients with allergic rhinitis and asthma have abundant mast 
cells in the nasal mucosa [68].  However, research has shown that some non-allergic asthma 
and rhinitis patients also show increased numbers of mast cells in their nasal mucosa, 
supporting the perception that a cohort of nonallergic patients have an inflammatory-type 
pathology, localized to the nasal mucosa. Further research unraveled an alternative IgE-
independent pathway mediated by immunoglobulin free light chains (FLCs) [68]. 
In healthy individuals FLCs are produced in abundance compared to intact 
antibodies. These FLCs have also been implicated to play a pivotal role in the pathogenesis 
of other inflammatory and autoimmune diseases like rheumatoid arthritis, multiple 
sclerosis, systemic lupus erythematosus and AIDS [67]. Several scientists have tried to 
demystify the biological role of FLCs and their results show that these proteins are capable 
of modulating the immune system and have the ability to bind antigens among other 
functions [67,68,76]. Despite that monomeric FLCs can also bind antigens, the structural 
features of dimeric FLCs resemble an antibody Fabs, therefore, the binding capabilities of 
dimers prevail over that of monomeric FLCs [77]. 
Less attention, however, has been given to the analysis of the peculiar functional 
properties of dimeric FLCs. Additional studies are needed to understand better the 
pathophysiology of nonallergic rhinitis that is mediated by FLCs. Among these, further 
studies are needed to identify which allergens can act as triggers in FLC-mediated mucosal 
immune responses. Measurement of FLCs and secretory IgE in nasal secretions from 




noticed formation of FLCs in HDM allergy, like we experienced with Der f 1 mAb 6A8, 
further research on the role FLC play in Group 1 HDM allergy are certainly warranted.  
 On a different note, to our knowledge, the current study on Group 2 HDM allergens, 
published in the Journal of Immunology [26] reports the first X-ray crystal structure of one 
of the most important major mite allergens, Der p 2, in complex with a murine IgG mAb 
7A1.  Structural analysis of the Der p 2.0103–7A1Fab complex demonstrated the flexibility 
of Der p 2 upon antibody binding. Superposition of the X-ray crystal structures of Der p 
2.0103 alone and in complex with the Fab of the mAb 7A1, revealed conformational 
changes in the allergen structure upon antibody binding. Antibody binding to one part of 
the allergen molecule was translated into conformational changes, even in distal parts of 
the molecule opposite to the mAb 7A1 epitope, which could potentially affect the binding 
of other antibodies. Nevertheless, either mAb 1D8 or αDPX could simultaneously bind Der 
p 2 even when the allergen was already bound to mAb 7A1.  
Overall, this study presented a detailed analysis of an IgE antibody binding site on 
the HDM major allergen, Der p 2. This was achieved by determining the X-ray crystal 
structure of Der p 2.0103–7A1Fab complex, combined with NMR studies. The epitope 
recognized by the murine IgG mAb 7A1 (which had been reported to overlap with an IgE 
antibody binding site on the allergen) was identified by studying the allergen-antibody 
binding interface on the Der p 2.0103–7A1Fab complex. Detailed analysis of the epitope 
defined critical residues for allergen-antibody interactions which led to a rational design of 
site-directed mutagenesis experiments. The epitope structure and subsequent mutagenesis 
analysis showed that residues 31, 33, 96, and 97 are important for IgE binding. These 




Allergen Nomenclature database (www.allergen.org). Accordingly, the mAb 7A1 
recognized all six variants tested: Der p 2.0101, Der p 2.0102, Der p 2.0103, Der f 2. 0101, 
Der f 2.0102, and Der f 2.0103 [78]. Therefore, the relevance of these finding in terms of 
design of hypoallergens could be extended to the cross-reactive allergen Der f 2 that is also 
recognized by mAb 7A1.  
 In addition, Eur m 2, Lep d 2, and Tyr p 2 variants have at least 1-aa substitution at 
one of the two positions mutated for each mutant, and these allergens are not recognized 
by mAb 7A1 [78]. These differences are the basis for cross-reactivity or lack thereof among 
group 2 allergens from different species [78]. Furthermore, when mAb 7A1 was used in 
ELISA assays with patient blood sera, it was shown to inhibit up to 39% of plasma IgE 
binding to Der p 2 for five mite-allergic patients, in agreement with an up to 30% inhibition 
previously reported in individual or pooled patients’ sera [79]. This shows the importance 
of mAb 7A1 epitope in human IgE binding. Overall, these findings indicate that mAb 7A1 
would be a good candidate for measuring Der p 2 in complex extracts used for diagnosis 
and immunotherapy, in contrast to other mAbs that do not recognize all the isoforms [80].  
The identification of amino acid substitutions involved in IgE binding will allow for a 
rational design of hypoallergens for better therapy, aiming to mitigate adverse reactions 
that are usually observed in conventional immunotherapy.  
1.21 FUTURE DIRECTIONS  
Studies by Chapman et. al revealed a fundamental finding which suggest that sometimes 
most epitopes defined by monoclonal antibodies derived from mice are not the same as, or 




repertoires of murine IgG and human IgE antibody put into question the integrity of using 
murine-derived mAb as surrogates in studying human IgE binding.  
Future studies on this HDM project aim to use human-derived monoclonal IgE 
antibodies instead of murine-derived IgG antibodies and promising preliminary results 
have already been elucidated using human derived mAb 2F10 in complex with Der p 
2.0103 produced by Dr. Pomés’ laboratory. For mAb 6A8, fusion proteins with leucine 
zippers, known to form hetero-dimeric proteins, will be made in the quest to make Fabs for 






Table 1.1: House Dust Mite Allergens 
 
The 39 HDM allergens officially registered by the WHO/IUIS Allergen Nomenclature 
Sub-Committee (www.allergen.org). Group 1 and 2 (Cysteine proteases and Niemann 




Table 1.2: IgE and IgG antibodies specific for Group 1 and 2 HDM allergens 
 
 
Antibody Type Antigen Progress 
1C14 IgE-IgG Der p 1 Unstable 
E11 IgE scFab Der p 1 Unstable 
4C1 Fab Der p 1 Crystallization 
6A8 Fab, scFv Der f 1 
Light Chain Dimer 
Structure 
2G1 Full IgE Der p 2 Crystallization 
5D10 Full IgE Der p 2 Crystallization 
1B8 Full IgE Der p 2 Crystallization 
αDPX Fab, scFv Der p 2 Unstable 
1D8 Fab, scFv Der p 2 Unstable 
7A1 Fab, scFv Der p 2 Fab Structure Solved 
2F10 Fab, Human IgE Der p 2 Structure Solved 




Table 1.3: Data collection, processing, and refinement  
















































Parameters for the highest resolution shell are in parentheses. ID,  
identifier; R.m.s, root-mean-square. 
Diffraction source APS Beamline 22ID 
Wavelength (Å) 1.0000 
Temperature (K) 100 
Space group C222 
a, b, c (Å) 123.7, 132.6, 65.4 
α, β, γ (°) 90.00, 90.00,90.00 
Resolution range (Å) 40.00-2.80 (2.80-2.72) 
No. of unique reflections 13125 (639) 
Completeness (%) 95.6 (94.4) 
Redundancy 3.4 (3.0) 
〈I/σ(I)〉 12.5 (3.1) 
Rmeasure 0.096(0.754) 
Rp.i.m. 0.049(0.410) 
Overall B factor from Wilson plot (Å2) 66.04 
CC1/2 (0.692) 
Rcryst 0.198 (0.247) 
Rfree 0.259 (0.302) 
R.m.s. deviations  
Bonds (Å) 0.013 
Angles (°) 1.6 
Average B factors (Å2) 66 
Ramachandran plot  
Favoured (%) 98.1 
Allowed (%) 1.9 





Table 1.4: Data collection, processing, and refinement  










































Parameters for the highest resolution shell are in parentheses. ID, 
identifier; R.m.s, root-mean-square [26]. 
PDB ID 6OY4 
Diffraction source APS Beamline 22ID 
Wavelength (Å) 1.0000 
Temperature (K) 100 
Space group C2 
a, b, c (Å) 180.1, 43.3, 106.0 
α, β, γ (°) 90.0, 125.3, 90.0 
Resolution range (Å) 40.00-2.45 (2.49-2.45) 
No. of unique reflections 23826 (1143) 
Completeness (%) 94.7 (92.4) 
Redundancy 3.0 (2.4) 
〈I/σ(I)〉 14.5 (2.2) 
Rmeasure 0.133 (0.547) 
Rp.i.m. 0.074 (0.325) 
Overall B factor from Wilson plot (Å2) 47.3 
CC1/2 (0.628) 
Rcryst 0.203 (0.257) 
Rfree 0.260 (0.312) 
R.m.s. deviations  
Bonds (Å) 0.011 
Angles (°) 1.4 
Average B factors (Å2) 42.9 
Ramachandran plot  
Favoured (%) 97 




Table 1.5: Hydrogen bonds formed between  
mAb 6A8 homodimer chains 
 
 Chain A Chain B Distance (Å) 
1 TYR 88 GLN 39 3.2 
2 GLN 39 GLN 39 2.8 
3 GLY 43 TYR 88 2.7 
4 GLN 125 SER 117 2.9 
5 SER 95 ARG 47 2.6 









































Figure 1.1: Project Flow Chart. The two main projects carried out in this research. Blue 





Figure 1.2: Superposition of structures of Group 1 and 2 HDM Allergens. (A) Group 
1 HDM allergens, Der f 1 (forest green; PDB: 5VPK) and Der p 1 (sand; PDB: 2AS8) share 
81% sequence identity, and (B) Group 2 HDM allergens, Der f 2 (ruby; PDB: 1XWV) and 





Figure 1.3: HDM Project Flow Chart. The two sections in green boxes are parts done by 
our collaborators, Dr. Anna Pomés and her group at Indoor Biotechnologies. Murine IgG 
antibodies were obtained from hybridomas developed by Dr. Martin Chapman at the 
University of Virginia. Human IgE constructs were isolated either from phage display 
combinatorial libraries by Dr. Mats Ohlin at Lund University (Sweden), or from Dr. Scott 
Smith at Vanderbilt University Medical Center using human hybridoma technology, as part 
of the R01R01AI077653 project. All IgE constructs were expressed either in mammalian 











Figure 1.4: Der p 2.0101 and Der p 2.0103 Sequence Alignment and SDS-PAGE for 
Der p 2.0101. (A) Sequence Alignment for Der p 2.0101 and Der p 2.0103 [81]. The two 
isoforms share 98% sequence identity (B) SDS-PAGE for Der p 2.0101 after Ni-NTA 


















Figure 1.5:  SDS-PAGE after Ni-NTA purification of isoform Der p 2.0103 and SEC 
Elution Profile. (A) SDS-PAGE after IMAC purification (B) SEC elution profile. The 
protein was obtained in monomeric form. The yield was 7 mg/L of culture. Myoglobin and 







Figure 1.6: Schematic diagram of immunoglobulin E and immunoglobulin G.  






Figure 1.7: Schematic diagram of antibody fragments. (A) Single chain variable 
fragments-scFv (i) heavy chain first in sequence then linker then light chain (ii) light chain 
linked to the N-terminus of heavy chain (B) Antibody fragment (Fab) Light chain and 





Figure 1.8: mAb 6A8 constructs generated over three years of research. Single chain 
variable fragments (scFv) (A) Long Linker (GGGGS)x3 (B) Short Linker (GGGGS)x2. 
(C) Antibody Fragment (Fab) with purification tag on both chains (D) Glutathione S 





Figure 1.9:  SDS-PAGE after Ni-NTA purification of 
mAb 6A8 scFv (short linker). Although the expression 
and solubility of the protein was considerably enhanced, 
the protein was very unstable. After SEC, the yield of the 





Figure 1.10:  SDS-PAGE after Ni-NTA purification of mAb 6A8 Fab and SEC Elution 
Profile. (A) SDS-PAGE after IMAC purification. The light chain was overexpressed than 
the heavy chain (B) SEC elution profile. The protein was obtained in monomeric form.  
The yield was 6-8 mg/L of culture. Vitamin B12, Myoglobin and Ovalbumin are shown as 





Figure 1.11: X-ray crystal structure of mAb 6A8 Light Chain Dimer. (A) Cartoon 





Figure 1.12: Superposition of mAb 6A8 light chain dimer and a 
kappa light chain dimer (PDB: 1B6D).  mAb 6A8 is in sky blue and 
1B6D in deep salmon. 6A8 light chain dimer has similar structural 






























Figure 1.13: X-ray crystal structure of mAb 6A8 Light Chain Dimer with 
CDRs highlighted and distribution of B factors. (A) Surface presentation with 
CDRs on top of the chains. Chain 1 is in sky blue and chain 2 is in firebrick. (B) 
Overall B-factors- mobility of mAb 6A8 light chain dimer. Red color and the larger 
diameter of ribbon correspond to the highest mobility/displacement of residues; 
blue color and the smallest diameter correspond to regions with the lowest mobility. 






Figure 1.14:  SDS-PAGE after Ni-NTA purification of 6A8 LL dimer and Der p 2.0103 
complex and SEC Elution Profile. (A) SDS-PAGE after SEC purification (B) SEC elution 
profile. Peak 1 is mainly 6A8 LL dimer and peak 2 is mainly Der p 2.0103 with a little 






Figure 1.15:  ELISA Binding Assays of 6A8 LL dimer to several allergens. 6A8 LL 
dimer binding to (A) Group 1 allergens (B) Group 2, Der p 2 and (C) random allergens and 
non-allergens. 6A8 LL dimer is non-specific and binds to random proteins. These 





Figure 1.16: Structure of Der p 2.0103–7A1Fab Complex. (A) Space filling 
representation of the complex (top). Der p 2 is shown in magenta, whereas L and H chains 
of the Ab are marked in light and dark gray, respectively. CDRs are mapped on mAb 7A1 
molecular surface and marked with different colors (bottom). (B) Interaction between the 
epitope and the paratope. Positions of water molecules buried between allergen and the Ab 
are marked with red spheres. For clarity of the presentation, only positions of water oxygen 
atoms are shown. (C) The inset shows the residues from epitope and paratope that are 
involved in formation of H-bonds (green dashed lines) and a cation-p interaction (blue 






Figure 1.17: Mobility of Der p 2 in the structure with the mAb 7A1 complex. (A) 
compared with Der p 2 alone (B). Comparison of B factors between mAb 7A1 bound (A) 
and free (PDB code: 1KTJ) Der p 2.0101 (B) Red color and the larger diameter of ribbon 
correspond to the highest mobility/displacement of residues; blue color and the smallest 
diameter correspond to regions with the lowest mobility. Other colors and diameters of the 
ribbon indicate intermediate mobility of the residues. (C) Superposition of main chains for 
mAb 7A1–bound (magenta) and –free (gray) Der p 2.0103. Ovals mark regions that display 
the most pronounced conformation differences. (D) Display of Der p 2 residues in x-ray 
crystal structures, associated with conformational changes of methyl residues in Der p 2 
observed by NMR (see Fig. 3). The ribbon diagram of Der p 2 alone (1KTJ) is colored 
green for residues that would interact with mAb 7A1, gray for other residues, and yellow 
sticks are shown for Ile28, Leu61, Val63, and Ile97. Der p 2 in the mAb 7A1 Fab complex 
is colored black, and Ile28, Leu61, Val63, and Ile97 are rendered with purple sticks. The 
Fab is rendered in dark red with a ribbon and mesh surface. (E and F) Structural changes 
of specific Der p 2 areas upon Ab binding. Magenta, Ab bound Der p 2.0103; gray, free 
Der p 2.0103 (PDB code: 1KTJ). (E) Zoom on a region that was marked in (C) with the 






Figure 1.18: Comparison of Tris and Phosphate Buffer in 7A1 scFv purification. 





Figure 1.19: SDS-PAGE after Ni-NTA purification and SEC Elution Profile of 
isoform Der p 2.0101 and 7A1 scFv complex. (A) SDS-PAGE shows the successful of 
co-expression of 7A1 scFv and Der p 2.0101. (B) The two proteins were in complex. 
Hence, one elution peak was obtained in SEC. Myoglobin and Ovalbumin are shown as 





Figure 1.20: Mutations abolished mAb 7A1 binding to Der p 2.0103. (A) Direct binding 
assay showing that the two Der p 2 mutants in the epitope for mAb 7A1 did not bind 
biotinylated mAb (B-mAb) 7A1, whereas both bound B-mAb 1D8 (positive control). Plot 
represents an average of two experiments. (B) Reduced capacity to inhibit patient’s IgE 
antibody binding by Der p 2 mutants versus the wild type. A reduction of the IgE Ab 
binding in different degrees by the two mutants was seen for all patients. Plot represents 





STRUCTURAL, FUNCTIONAL AND IMMUNOLOGICAL STUDIES OF 
PROFILIN ALLERGENS FOR COMPONENT RESOLVED ALLERGY 
DIAGNOSTICS AND IMMUNOTHERAPY1,2
 
2.1 BACKGROUND AND INTRODUCTION TO PROFILINS 
Worldwide, there are thousands of allergens known to cause allergies and they 
afflict more than one-third of the population [2]. These allergens are grouped into over a 
hundred allergen families [3] and a significant fraction of officially registered allergens 
originates from the profilin family of proteins. Profilins are ubiquitous proteins that were 
discovered for the first time more than 40 years ago in calf thymus [85]. These small (12–
15 kDa) and typically eukaryotic proteins have been proven to be involved in regulating 
various cellular processes including membrane trafficking, actin cytoskeletal dynamics, as 
well as binding to proline-rich regions of proteins [85,86].  
_____________________________________ 
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Along with proteins like cyclophilins, nonspecific lipid-transfer proteins, and 
polcalcins, profilins are also considered to be panallergens [10]. These pervasive proteins 
share high sequence identity and similarity (Figure 2.1) and have extremely conserved 
three-dimensional structures [87]. This explains why high IgE cross-reactivity is observed 
among panallergens [9]. However, currently only plants and mites have been identified as 
sources of allergenic profilins [9]. 
Plant profilins registered as allergens have high sequence identity (at minimum 
65%), even between relatively distant related members such as weeds and fruits [88]. 
Allergenic plant profilins originate from pollens of weeds, trees, and grasses, in addition 
to fruits, legumes, seeds and vegetables [10]. Therefore, profilins account for pollen-food 
syndrome. Moreover, between 10–30% of patients allergic to pollen are also sensitized to 
profilins [89,90]. Profilins have also been indicated as being responsible for food allergy 
depending on sensitization to cross-reactive pollens in the mugwort-celery-spice syndrome 
and ragweed-melon allergy [91,92]. A broad range of plant-derived food products contain 
profilins including fruits, legumes, nuts, and vegetables [9]. It is commonly accepted, 
however, that profilin-dependent allergic reactions to food result from cross-reactivity 
between pollen and food profilins where the former are true sensitizers [93,94]. Although 
some profilins can elicit adverse immune responses such as anaphylaxis, the infrequent 
systemic reactions observed in patients after oral exposure to profilins is due to their low 
stability and high susceptibility to denaturation by proteases in the acidic environment of 
the digestive tract [83,95].   
Although several other profilins were characterized in this research, Cuc m 2.0101, 




(mugwort) and Phl p 12.0101, a profilin from Phleum pratense (Timothy grass), will be 
discussed herein. Despite a majority of the allergenic profilins being considered as minor 
allergens, [89] Cuc m 2.0101 can elicit IgE production in 80% of muskmelon allergic 
patients. As such, Cuc m 2.0101 is regarded as a major allergen [96]. Muskmelons are 
found throughout the world and are commercially grown in Turkey, the USA, Spain, 
Morocco, India and other countries [97]. Cuc m 2 is one of the most important melon 
allergens, and in general, melon allergy is one of the most common food allergies [98]. 
Food allergies are characterized by symptoms in the skin, gastro-intestinal tract, and 
respiratory system, resulting in oral itching, lip swelling, and labial edema, or [99].  Cuc m 
2, specifically, primarily elicits oral itching and lip swelling symptoms [100].  
On the other hand, Artemisia vulgaris, known colloquially as mugwort, is another 
known source of profilins. It is a member of the Asteraceae family found in temperate 
regions of the northern hemisphere, the Mediterranean basin, and parts of Asia [101]. 
Patients with mugwort sensitivity often experience ragweed sensitivity as a result of co-
recognition of the major allergens from each plant rather than cross-reactivity of common 
antigens [101]. It is noteworthy that A. vulgaris is one of the few important allergenic 
sources causing allergic diseases in 10–14% of pollinosis (pollen allergy) patients 
[102,103]. Art v 4.0101, an A. vulgaris profilin, is a clinically significant weed allergen 
[88] that has a sensitizing prevalence of 34–36% in Europe [104].  
The third profilin studied, Phl p 12.0101, stems from Timothy, a perennial grass 
native to most of Europe and found in most of the United States [84].  Due to this ubiquitous 
nature of Timothy grass, it is a potent source of allergens for many sensitized patients.  




response prevalence and strength as Phl p 1, a major allergen from Phleum pratense [105].  
In addition, it is released from Timothy grass pollen in the same timeframe as the other 
Timothy grass allergens and in similar amounts as Phl p 1 [105].  Phl p 12.0101 also has 
high sequence identity (76 %) to Cuc m 2.0101 and the potential for cross-reactivity 
between the two profilins is high [9]. 
In this research, the structural, molecular, and thermal stability characteristics, as 
well as, possible IgE cross-reactivity between profilins was investigated. Firstly, the 
recombinant versions of the three profilins were expressed in E. coli and two of the proteins 
were crystallized. Secondly, to develop new insights into the allergenicity of profilins, the 
thermal stability of this family of proteins was compared using Differential Scanning 
Fluorimetry (DSF). The combination of structural and thermal stability studies offers 
explanations for the molecular basis of various clinical syndromes observed involving 
profilins (Figure 2.2). Lastly, Art v 4.0101 and Phl p 12.0101 were tested for their ability 
to bind patient-derived antibodies to establish sensitizing patterns in children and adult 
patients from North-East Poland—a region abundant in birch, timothy grass, and mugwort, 
but with no ragweed. Studying the molecular and immunological characteristics of Cuc m 
2.0101, Art v 4.0101 and Phl p 12.0101 will clarify the clinical relevance of these important 
profilins in allergy sensitization and their possible contribution to pollen-food syndrome. 
Comparison of profilins molecular, structural and antigenic properties provides new 
insights into the allergenicity of this family of proteins, expedite allergy diagnostics and 







2.2 PRODUCTION OF RECOMBINANT PROFILINS CUC M 2.0101, ART V    
      4.0101AND PHL P 12.0101 
 
Genes coding for Cuc m 2.0101 and Art v 4.0101 were synthesized and inserted in 
pJExpress411 plasmid by DNA 2.0 (currently ATUM, Newark, CA). Phl p 12.0101 was 
synthesized and inserted in pET26b (+) plasmid by Bio Basic (Amherst, NY, USA). The 
inserts were designed with a cleavable N-terminal purification tag 
MHHHHHHSSGVDLGTENLYFQ/SGSG, where the slash denotes the Tobacco Etch 
Virus (TEV) protease cleavage site. The plasmids were transformed into E. coli BL-
21(DE3) or BL-21 (DE3) pLysS cells in the case of Cuc m 2.0101. Cultures were grown 
in LB with 50 μg/mL kanamycin at 37 °C to an OD600 of 0.4. Cultures were then cooled to 
22 °C and grown to an OD600 of 0.8 and induced with IPTG at a final concentration of 0.5 
mM, cooled to 16°C, and grown for 16–18 hours. Cell pellets were resuspended in lysis 
buffer (50 mM Tris−HCl, 500 mM NaCl, 2% glycerol, 20 mM β-mercaptoethanol (β-ME), 
10 mM imidazole, pH 7.4) and lysed by sonication. The sonicated mixture was centrifuged 
at 9000 x g for 10 min at 4°C. The supernatant was loaded onto a Bio-Rad Econo-Pac 
chromatography column containing Thermo- Scientific HisPur Ni-NTA resin equilibrated 
with the same lysis buffer. The protein was eluted using elution buffer (50 mM Tris−HCl, 
50 mM NaCl, 2% glycerol, 20 mM β-ME, 250 mM imidazole, pH 7.4). Elutions containing 
protein were determined by SDS-PAGE, pooled and dialyzed overnight using Pierce 
SnakeSkin Dialysis Tubing with a molecular weight cutoff of 3,500 Da and dialysis buffer 
(50 mM Tris−HCl, 150 mM NaCl, pH 7.4). The dialyzed proteins were concentrated using 
a Millipore Amicon Ultra concentrator with a 3,000 Da molecular mass cutoff and was 






The proteins were observed to be predominantly monomeric based on SEC results 
(Figure 2.3). However, a small fraction of the produced protein was present in a dimeric 
form. Due to the small amount of the produced dimeric form, only the monomeric form of 
the protein was studied further. Fractions containing the monomeric protein were 
concentrated and protein concentration was determined spectrophotochemically measuring 
absorption at 280 nm using a Thermo-Scientific Nanodrop. TEV protease was used to 
cleave the purification tag from the profilins according to the protocol previously described 
[106]. For crystallization experiments, the proteins (stored in 50 mM Tris−HCl, 150 mM 
NaCl, pH 7.4) were concentrated to 12, 25 and 40 mg/mL. The concentration was measured 
spectrophotochemically at 280 nm using a Thermo-Scientific Nanodrop [83]. The yield of 
the profilins were as follows: Phl p 12 - 70mg/L, Cuc m 2 - 40mg/L and Art v 4 - 25mg/L 
of culture. The proteins were used for circular dichroism to ensure proper folding, thermal 
stability studies using DSF, crystallization experiments, and sensitization studies using 
patient blood sera.  
2.3 CIRCULAR DICHROISM SPECTROSCOPY (CD) 
 
The three-dimensional structure of an allergen plays a crucial role in its function 
and allergenicity [34]. To test folding of the proteins in their native form, circular 
dichroism, which estimates the secondary structure of a protein, was employed. In addition, 
although the X-ray crystal structure for Cuc m 2.0101 was eventually obtained, no 
diffracting quality crystals have been obtained for Phl p 12.0101 to date; hence, the 
secondary structure of the proteins (with purification tag intact for Cuc m 2 and without 
purification tag for Phl p 12) had to be estimated using circular dichroism spectroscopy 




obtained. Protein samples for CD experiments were desalted using Sephadex® beads 
previously equilibrated in 10 mM sodium phosphate buffer that had been adjusted to pH 
7.4 using phosphoric acid. The samples were concentrated to 40 μM following the same 
method mentioned previously. The instrument was operated according to the 
manufacturer’s protocol at a wavelength range of 220–320 nm. Data processing was done 
using CAPITO software and the secondary structure percentages were calculated [107]. 
For comparison purposes we used the Cuc m 2.0101 structure elucidated here (PDB code 
6MBX) and secondary structure definitions assigned by DSSP software [61].  
Cuc m 2.0101 (with purification tag) secondary structure was estimated as follows: 
α-helices 0–27%, β-strands 30–48% and loop regions (irregular) 43–58% [107]. These 
results are in agreement with the secondary structure calculated using the crystal structure 
of Cuc m 2.0101 reported here (α-helices 24%, β-strands 35% and loop regions (irregular) 
41%) [83]. The secondary structure of Phl p 12.0101 too was estimated by CAPITO to be 
as follows (according to similarity hits based on 25 nearest neighbors): α-helices 9–16%, 
β-strands 32–48%, and loop regions (irregular) 42–58% [107]. These results are similar to 
the secondary structure calculated using the crystal structure of Cuc m 2 [83,84]. This data 
strongly suggests that both recombinant Cuc m 2 and Phl p 12 were properly folded.  
2.4 THERMAL STABILITY OF PROFILINS: DIFFERENTIAL SCANNING  
      FLUORIMETRY (DSF) 
 Differential scanning fluorimetry was used to investigate the thermal stability of 
Cuc m 2.0101, Art v 4.0101 and Phl p 12.0101 with and without purification tag. DSF 
experiments were carried out using Bio-Rad CFX96 RT-PCR instrument. All solutions 
were made as an in-house salt gradient and pH screen. A working concentration of 50 mM 




increments) and a salt range (sodium chloride) 0−1.0 M (no salt, 0.05, 0.10, 0.15, 0.20, 
0.25, 0.50, and 1.0 M). All experiments and steps were done according to the procedures 
described previously [106]. To determine the melting temperatures of the profilins in each 
condition, Bio-Rad CFX Manager software was used to calculate the inflection point of the 
melting curves. Each experiment was performed three times and an average melting 
temperature (Tm) was calculated [83,84].  
Since the melting temperatures for all the 63 allergenic profilins could not 
experimentally tested, theoretical melting temperatures for these profilins were calculated 
with Tm Predictor [108]. To identify allergenic profilins and obtain amino acid sequences 
that correspond to the mature forms of the proteins to use in the Tm Predictor, a search was 
performed using the Allergome and AllFam software (Table 2.2) [3,109]. Allergen.org was 
used to identify officially registered allergens [7].  
The results for the DSF experiments performed for Cuc m 2.0101 (Figure 2.4) show 
that the maximum melting temperature (56°C) is similar to those observed for previously 
characterized Amb a 8.0101 (profilin from ragweed), Art v 4.0101, and Bet v 2.0101 
(profilin from birch) [106]. From the melting temperatures acquired, Cuc m 2.0101 with 
the purification tag was slightly more stable than with the cleaved tag. The salt 
concentration did not have a major impact on Cuc m 2.0101 thermal stability, with the only 
exemption being pH 4.0 for the protein with the purification tag. In comparison with Amb 
a 8.0101, Art v 4.0101 and Bet v 2.0101 (birch profilin) studied previously [106], the 
muskmelon profilin is significantly more stable in solutions with lower pH values. For 
example, when Cuc m 2.0101 is compared with Art v 4.0101, the muskmelon protein is 




in solutions with pH between 4.0 and 5.0. In these conditions, Cuc m 2.0101 has melting 
temperatures 8–19°C higher in comparison with Art v 4.0101 (Figure 2.4B), Amb a 8.0101, 
and Bet v 2.0101. The biggest differences are observed for solutions with pH 4.0. 
For the thermal stability of Phl p 12.0101, the DSF results performed show that the 
protein without purification tag was more stable with Tm difference as high as 6ºC than 
with the tag intact (Figure 2.5).  Both versions of the protein, however, are most stable 
between pH 5.0 to 8.5 and least stable between pH 4.0 to 4.5. Salt concentration does not 
have a major impact on Phl p 12.0101 thermal stability, with the only exemption being 
seen at 1 M NaCl for the protein with the purification tag. Generally, in comparison with 
Art v 4.0101, Bet v 2.0101 and Amb a 8.0101, Phl p 12.0101 without purification tag is 
more stable than the other two profilins (Figure 2.5B-D). Comparison of the DSF results 
between Cuc m 2.0101 and Phl p 12.0101 shows that the stability of Phl p 12.0101 is the 
most similar to Cuc m 2.0101 than all the other profilins studied. 
 However, the timothy grass profilin is significantly more stable in solutions with 
lower pH values both with and without the purification tag. For example, when Phl p 
12.0101 is compared to Art v 4.0101, Cuc m 2.0101 and other profilins studied [84], the 
protein is clearly more stable in the 4.0 to 6.0 pH range, and the differences are especially 
pronounced in solutions with pH between 4.0 and 5.5. In these conditions, Phl p 12.0101 
has Tm 7-26°C higher in comparison with Cuc m 2.0101, Amb a 8.0101), Art v 4.0101 and 
Bet v 2.0101 (Figure 2.5B-D). The biggest differences were observed for solutions with 
pH range 4.0 to 5.0. On the other hand, Phl p 12.0101 with the purification tag was nearly 




concentration, Phl p 12.0101 with purification tag was significantly less stable than Amb a 
8.0101, Art v 4.0101, and Bet v 2.0101 with Tm difference as high as 11ºC (Figure 2.5D). 
To compare the thermal stability of profilins, a computational approach was used 
as described by Ku et al. [108]. This approach allowed to divide allergenic profilins into 
three categories (Table 2.2). The first category includes proteins that have a predicted 
melting temperature above 65°C, and only one profilin (Vit v 4, grapevine) was predicted 
to belong to this group. The second category includes proteins melting in the 55–65°C 
range, and there are several allergenic profilins predicted to be in this group (Cap a 2 (bell 
pepper), Citr l 2 (watermelon), Cor a 2 (hazel), Cuc m 2 (muskmelon), Gly m 3 (soybean), 
Mal d 4 (apple), Par j 3.0201 (pellitory of the wall), Pha v 5 (bean), Pru av 4 (cherry), Pru 
du 4 (almond), Pru p 4 (peach), Sola l 1 (tomato), Sola t 8 (potato) and Tyr p 36 (storage 
mite)). The third and most numerous group includes profilins that have melting temperature 
predicted to be below 55°C. The predicted melting temperatures agree with the 
experimental results for Amb a 8.0101, Art v 4.0101, Bet v 2.0101 and Cuc m 2.0101 [106]. 
In summary, our findings support the same conclusion as alluded to by other researchers 
who classified profilins as labile proteins [110-112] and this might explain why most of 
these profilins are regarded to as minor allergens. Thermal stability studies of profilins help 
explain the molecular basis of the allergenicity of these group of allergens, however, 
structural studies were still needed to decipher the influence of profilins structure in both 
IgE cross-reactivity and immunogenicity. 
2.5 CRYSTALLIZATION OF CUC M 2.0101 AND ART V 4. 0101 
Crystallization of Cuc m 2.0101 was performed at 277 K. The best quality crystals 




were grown using the sitting drop vapor diffusion method. The best diffracting Cuc m 
2.0101 crystals were obtained when 40 mg/mL protein sample was mixed 1:1 with well 
solution containing 2.8M sodium acetate, pH 7.0. Prior to data collection, Cuc m 2.0101 
crystals were cryo-protected using 50% glycerol solution, then immediately cryo-cooled in 
liquid nitrogen. Art v 4.0101 was crystallized at 293 K in MRC 2-drop 96-well 
crystallization plates (Molecular Dimensions) by mixing 0.49 M sodium phosphate 
monobasic pH 6.9 (Hampton Research Index Screen) with recombinant protein in a 1:1 
ratio. 
2.6 DATA COLLECTION AND STRUCTURE DETERMINATION 
Data for the new crystal form of Art v 4.0101 was collected remotely using the 
Southeast Regional Collaborative Access Team (SERCAT) 22-ID beamline at the 
Advanced Photon Source (APS), Argonne National Laboratory. Data for Cuc m 2.0101 
was collected at the 19-BM beamline of the Structural Biology Center, APS. Diffraction 
images of each protein were processed with HKL-2000 [113]. The structures of Cuc m 
2.0101 and Art v 4.0101 were solved by molecular replacement using MOLREP [53] and 
HKL-3000 [52] with the previously published structure of Art v 4.0101 (PDB code 5EM0) 
as the starting model [88]. The models were rebuilt using BUCCANEER [54] and COOT 
[58]. The structures were refined using REFMAC [56] and HKL-2000. Various programs 
from the CCP4 package [57] were used for data analysis. COOT and MOLPROBITY [59] 
were used for validation of models. Both structures together with structure factors were 
deposited into the Protein Data Bank [114] with accession codes 6B6J and 6MBX for Art 





2.7 STRUCTURAL ANALYSIS OF CUC M 2.0101 AND ART V 4.0101 
 The Cuc m 2 crystal structure was determined at 2.4 Å (PDB code 6MBX). Cuc m 
2.0101 (155 amino acid residues – including the N-terminal purification tag) crystallized 
in the C2 space group with three molecules in the asymmetric unit (Table 1). The crystal 
structure could be also solved in P3221 space group (one molecule in the asymmetric unit); 
however, in this case, the refinement and model update were not able to reduce the Rfree 
value below 35%. Residues corresponding to the purification tag were not visible in the 
electron density map and absent from the final model. Similar to other allergenic profilins, 
like Art v 4.0101 (Figure 2.6), Cuc m 2.0101 also exhibits a crystal structure with three α-
helices and seven-stranded antiparallel β-strands. Interestingly, Cuc m 2.0101 with the 
cleaved tag crystallized as well, and the crystals were isomorphous (had very similar unit 
cell parameters and the same symmetry) to those formed by protein with the purification 
tag. However, their diffraction quality was poor, and their structural analysis was not 
pursued. 
The structure of a new crystal form of Art v 4.0101 was determined at 1.9 Å (PDB 
code 6B6J). The protein crystallized in the P31 space group with one molecule in the 
asymmetric unit. The previously determined Art v 4.0101 structure (PDB code 5EM0) was 
derived from an orthorhombic form of the protein (P21212 space group). Both Art v 4.0101 
structures superpose with RMSD value of 0.5 Å over 133 aligned Cα carbons which 
illustrates highly similar conformations of the protein main chain. The overall structure is 
similar despite the fact that the protein structures were obtained from crystallization 
conditions that differed in pH (8.5 for 5EM0 and 6.9 for 6B6J reported here). Both Art v 




crystal forms. On the other hand, however, previous studies have shown that natural and 
recombinant Art v 4 can form dimers and tetramers that exhibit increased allergenicity and 
are stabilized by intermolecular disulfide bonds or ionic interactions [115]. Furthermore, 
Amb a 8.0101, Hev b 8, Zea m 12, and several others are reported to be present in 
monomeric or dimeric states [116]. In the case of Hev b 8 and Zea m 12, the dimer 
formation is also associated with creation of an intermolecular disulfide bond. This 
covalent bond is formed between Cys13 from two different molecules [116]. Art v 4 has 
three cysteine residues (Cys13, Cys95 and Cys117) and structural data indicates formation of 
an internal disulfide (SS) bridge between Cys95 and Cys117 (Figures 2.6 and 2.7). Such an 
SS bridge is not observed in Cuc m 2, despite having two cysteines (Cys13 and Cys115). 
Interestingly, two different crystal structures with Cys13 and Cys117 oxidized or reduced 
were reported for Bet v 2 [117]. 
Over 60 allergenic proteins analyzed (Table 2.2), only thirteen of them (Aca f 
2.0101, Ama r 2.0101, Ama v 2.01, Ama v 2.02, Amb a 8.0101, Art v 4.0101, Art v 4.0201, 
Hel a 2.0101, Koc s 2.0101, Pro j 2.0101, Sal k 4.0101, Sal k 4.0201 and Vit v 4) have 
conserved Cys95 and Cys117 (based on Art v 4.0101 residue positions). We predict that all 
these profilins most likely will have an intramolecular disulfide bridge formed by the Cys95 
and Cys117. Interestingly, all of the analyzed allergenic profilins have conserved Cys13 and 
Cys117. We also presume that all these allergenic profilins can possibly form dimeric 
assemblies that were described for Hev b 8, which involve formation of a disulfide bridge 
between two Cys13 residues from different molecules [116]. In this research, with Cuc m 2 
and Art v 4, the formation of dimeric proteins was also observed although they were in 




been shown to influence IgE binding [115,116]. To demonstrate how formation of dimeric 
proteins will influence IgE binding for Cuc m 2 using structural studies, IgE epitopes were 
mapped on the Cuc m 2 experimental model and compared to the dimeric crystal structure 
of Hev b 8. 
2.8 IgE EPITOPES 
Profilins represent one of the most numerous allergen families associated with 
many clinical syndromes. Some of them, (Cit s 2, Citr l 2, Cuc m 2 and Gly m 3) being 
major allergens, have instigated many researchers to investigate IgE epitopes associated 
with these proteins [118,119,96,120]. In a study to characterize IgE epitopes of Cuc m 2 
by López-Torrejón and colleagues, four IgE epitopes of Cuc m 2 were described (Figure 
2.8) [121]. Two of these epitopes were defined as major (E1 – residues 66–75 and 81–93; 
E2 – residues 95–99 and 122–131), because they showed the strongest IgE-binding 
capacity, and two additional epitopes (E3 – residues 2–10; E4 – residues 35–45) showed 
low IgE-binding capacity. Later, another sequence was identified—
S2W3A5Y6D9H10T111P112 G113Q114N116M117R121L122 as forming a Cuc m 2 mimotope 
(Figure 2.8) [89]. These studies were used to design Cuc m 2 mutants with reduced IgE-
binding capacities [89]. Interestingly, the mimotope overlaps mainly with epitope E3 
(Figure 2.8) and a significant area of the mimotope does not correspond to any of the 
identified IgE epitopes.  
Using structural studies, Cuc m 2 (surface representations) was superposed on one 
of the molecules forming the Hev b 8 dimer which demonstrated that formation of a dimeric 
structure would interfere with IgE biding to epitopes E2 and E3, as well as to the mimotope 




profilins is interesting not only in research but has important implications in allergy 
sensitizations. Lastly, as mentioned before, profilins are involved in several clinical 
syndromes including pollen-food syndrome. To observe sensitization patterns of profilins 
and their possible role in pollen-food syndrome, sensitization studies were carried out in 
100 patients with an established record of sensitization to pollen and plant-derived food 
allergens. 
2.9 SELECTION OF PATIENTS AND ANTIBODY BINDING STUDIES 
This part of the research was carried out by our collaborators Dr. Kowal and his 
group at the Medical University of Bialystok and the results were published in Molecules 
[84]. However, all the assays were performed using recombinant profilins produced in the 
Chruszcz laboratory. One hundred allergic patients, including 50 children and 50 adults 
sensitized to pollen and plant-derived food allergens, were included.  Patients with parasitic 
infection, autoimmune and systemic diseases, chronic respiratory diseases of non-allergic 
background, or immunosuppressive therapy were excluded from the study. Prior to the 
study, none of the patients had undergone treatment using allergen immunotherapy. This 
immunotherapy operated through the assessment of specific IgE (sIgE) antibodies’ 
interaction with individual allergen sources using a multiparameter immunoblot polycheck 
(Biocheck, GmbH, Münster, Germany) according to the manufacturer’s protocol [84]. All 
sera were tested for IgE reactivity to a panel of recombinant pollen profilins Amb a 8.0101, 
Art v 4.0101, Bet v 2.0101, and Phl p 12.0101 which previously had been structurally and 
immunologically characterized [88].  
Sensitization to profilins was demonstrated in 9 P+ among 50 studied children 




reaction to the profilin. The prevalence of sensitization to profilins in our population was 
similar to that reported previously in other populations of patients suffering from pollen 
allergy [122-124]. In each P+ patients, IgE reactivity to all four studied profilins (Amb a 
8.0101, Art v 4.0101, Bet v 2.0101, and Phl p 12.0101) was found (Figure 2.10). 
Sensitization to each profilin detected in each P+ patient reflected high structural 
similarities and immune cross-reactivity among plant-derived profilins (Figure 2.11) [88]. 
However, in a majority of patients sensitized to profilins, the greatest intensity of IgE 
binding was demonstrated for Phl p 12.0101 with 7 of 20 (35%) P+ patients and Art v 4 in 
6 of 20 (30%) P+ patients [84].  
2.10 DISCUSSION  
Profilins are proteins defined by their pervasive and abundant nature as well as their 
high IgE cross-reactivity, by definition of a panallergen. These proteins share very high 
sequence similarity and identity even among distantly related sources [87].  Due to this, 
profilins are important players in allergen cross-reactivity.  Although usually denoted as 
minor allergens, profilins can sometimes be recognized by IgE by more than 50% of a 
cohort of profilin sensitized patients [10].  Cuc m 2, a profilin from muskmelon, is 
recognized by IgE in more than 80 % of sensitized individuals and is one of the most 
important melon allergens with melon allergy being one of the most common food allergies 
[98].  Melon allergy has been indicted as eliciting several cross-reactions with birch, 
ragweed, and Timothy grass [9].  One such potentially cross-reactive profilin with Cuc m 
2 is Phl p 12 from Timothy grass.  Phl p 12 is a minor allergen that shares 76% amino acid 
identity with Cuc m 2. Thus, chances of cross-reactivity between the two allergens is high.  




exhibits comparable T cell response frequency and strength as Phl p 1, a major allergen 
also from Timothy grass. To exacerbate the situation, Phl p 12 is released simultaneously 
and in the same amount as Phl p 1 [105].   
The molecular, structural, and immunological properties of Cuc m 2, Art v 4 and 
Phl p 12 were investigated.  Although there are reports that some profilins are able to 
assume several oligomeric states, both Cuc m 2 and Phl p 12 were expressed and purified 
as primarily monomeric [115].  The thermal stability of profilins plays a major role in their 
allergenicity; generally, profilins are known as thermally labile.  DSF experiments for both 
Cuc m 2 and Phl p 12 showed the profilins’ intrinsic thermal instability.  Both Cuc m 2 and 
Phl p 12 had the highest melting temperature at 56°C. This might explain why most 
profilins are minor allergens since some of them, in particularly food allergens, have to go 
through high temperature food processing.  However, Cuc m 2 is recognized as a major 
allergen perhaps due to the fact that melons are usually eaten raw. 
Results of the maximum melting temperature predictions for the allergenic profilins 
are consistent with our experimental data, and indeed they show almost all profilins being 
thermally labile (Table 2.2). Predicted, relatively high melting temperature (> 65°C) for 
Vit v 4 will require an experimental confirmation. Predictions of thermal stability also 
show that there may be a subgroup of more stable allergenic profilins (melting in the 55–
65 °C range). This subgroup includes not only Cuc m 2.0101, but also Citr l 2.0101 and 
Gly m 3.0101, major allergens originating from watermelon and soybean, respectively. 
Interestingly, both DSF and melting temperature predictions indicate the presence of 




experimental results showing that Art v 4 and Cuc m 2 have a similar maximum thermal 
stability, despite the Tm Predictor classifying the Art v 4 as less stable. 
Structural studies reveal that Art v 4.0101 and Cuc m 2.0101 have similar main 
chain conformations as well, which reflects 80% sequence similarity and 70% sequence 
identity. The experimental structures of the two afore mentioned proteins, together with 
structures reported for Amb a 8, Ara h 5, Bet v 2, Hev b 8 and Zea m 12, provide insight 
into molecular properties of allergenic profilins. The intramolecular disulfide bridge is not 
critical for maintaining proper folding for the profilins. In addition, there are no significant 
changes in the structure of these molecules in the presence or absence of the disulfide 
bridge [83]. Analysis of recent profilin structures provides a more elaborate picture of 
possible quaternary assemblies which may be present in this group of proteins. In the case 
of recombinant Hev b 8, the formation of the dimeric assembly resulted in an increase of 
IgE-mediated degranulation of rat basophilic leukemia cells [116]. Comparison of 
monomeric structure of Cuc m 2 and the dimeric structure of Hev b 8 highlight implications 
of the dimer formation (Figure 2.9). For example, it is clear that the dimer formation would 
partially block residues forming epitopes E2 and E3 determined by López-Torrejón et al. 
(Figure 2.9A) and completely block the mimotope found by Tordesillas et al. (Figure 
2.9D). However, the studies of Cuc m 2 epitopes and the mimotope show the existence of 
IgE antibodies having the ability to recognize residues part of a Cuc m 2.0101 dimerization 
interface. 
As alluded to by the Hev b 8 example above, the oligomerization state of a profilin 
appears to play a major role in IgE response. This prompts a question about the 




body is exposed, and what differences in IgE response these states elicit. It is also worth 
noting that the residues forming the 674 Å2 dimer interface in Hev b 8 are almost 
completely conserved in Cuc m 2.0101 (Figure 2.9D), and this is also true for Art v 4.0101. 
Critics concur that the oligomerization of profilins warrants further research and may have 
various biological implications [125]. Moreover, profilins are involved in a plethora of 
molecular interactions, some involving the binding to proline-rich regions of various 
proteins [126]. Comparison of the dimeric structure of Hev b 8 with model of Amb a 8 in 
complex with polyproline (Figure 2.9B) implicates profilin dimerization also limits the 
ability of the protein to interact with the proline-rich peptides due to the oligomerization 
interface and the peptide binding sites partial overlapping. Conversely, the presence of both 
monomeric and dimeric forms of a profilin could be a meticulous solution that can be used 
in cells to modify affinity of the protein to various binding partners. Currently, how the 
structure of tetrameric assemblies reported for Art v 4 is also not known [115]. It is possible 
that the tetramer may be considered as a dimer of covalently linked dimers, as it was 
determined for Hev b 8. 
For the allergen sensitization studies of profilins, sensitizations to all studied 
profilins detected in each patient (n=100) reflected high structural similarities and immune 
cross-reactivity among plant-derived profilins. In a majority of patients sensitized to 
profilins, the greatest intensity of IgE binding was demonstrated by Phl p 12.0101. It has 
been proposed that sensitization to profilins depends on the intensity of exposure to 
individual allergen sources with grass pollen being the most important [127]. However, in 
some populations of birch and grass allergic patients, the frequency of sensitization to 




in those populations from central Europe, sensitization to profilins was more frequently 
observed in children than in adults. Furthermore, there appears to be a correlation between 
age and profilin sensitization as exemplified by a longitudinal study of molecular spreading 
of sensitization to individual allergens in timothy grass. The allergic children demonstrated 
that binding of IgE to profilins occurs late and usually after sensitization to major allergens 
such as Phl p 1 and Phl p 5 is well developed [129].  The greatest frequency of sensitization 
to profilins was not achieved earlier than 5 years after the onset of clinical symptoms [129]. 
Similar observations concerning age and sensitization to profilins was made in a large 
population of Italian children with allergic rhino conjunctivitis [122].  
 The above-mentioned findings support our results. In this research, no association 
between clinical symptoms of pollen-allergy syndrome and sensitization to profilins could 
be found. This indicates that sensitization to profilins was not necessary for development 
of pollen-food syndrome in young children. Moreover, these findings indicate the 
syndrome should be dependent on sensitization to other cross-reacting allergen 
components such as pathogenesis related protein family (PR-10) allergens. In summary, 
this study demonstrated that the presence of IgE for profilins in patients with pollen-food 
syndrome is quite frequent. However, no clinical significance of that sensitization among 
patients living in the area where birch pollen is a dominant tree allergen source could be 
demonstrated. Ragweed is not present in North-East Poland, but reaction to Amb a 8.0101 
was observed. This is caused by the high sequence and structure similarity between the 
profilin originating from ragweed and other studied profilins. Further studies are warranted 
to clarify the role of individual allergen sources in the process of sensitization to individual 




2.11 FUTURE DIRECTIONS  
After much deliberation, our findings reiterate the same results obtained previously 
by other researchers that profilins are thermally labile. However, in the results presented 
herein for the predicted thermal stabilities, there are profilins such as Vit v 4 (Tm >65 °C) 
which were predicted to be relatively stable compared to all other profilins. These melting 
temperatures will require an experimental confirmation.  Additionally, through structural 
studies we predicted that all profilins that have conserved Cys95 and Cys117 (based on Art 
v 4.0101 residue positions) will have an intramolecular disulfide bridge. Experiments must 
be performed to substantiate this prediction.  
Furthermore, we presume that all analyzed allergenic profilins with conserved 
Cys13 and Cys117 have potential to form dimeric assemblies, as observed for Hev b 8, which 
involves formation of a disulfide bridge between two Cys13 residues from different 
molecules. Again, only experiments can verify these claims. A good experiment to 
demonstrate the importance of Cys13 for the formation of these dimeric proteins, would be 
to produce mutants of Cys13 to serine. Finally, as discussed above, the oligomeric states of 
allergens in their natural form have far-reaching effects on IgE binding. Studying how the 
oligomeric state of profilins will influence IgE binding will certainly be a worthwhile goal 
to examine the basis of the allergenic potency of some profilins that are denoted as major 
allergens.  Henceforth, antibodies specific to major allergens will be produced and 






Table 2.1: Data collection, processing and refinement statistics for  








































Parameters for the highest resolution shells are in parentheses [83]. 
Protein/PDB code Art v 4.0101/6B6J Cuc m 2.0101/6MBX 
Diffraction source APS 22-ID APS 19-BM 
Wavelength (Å) 1.000 0.979 
Temperature (K) 100 100 
Space group P31 C2 
a, b, c (Å) 32.7, 32.7, 81.8 102.6, 59.2, 82.9 
α, β, γ (°) 90.00, 90.00, 120.00 90.00, 90.02, 90.00 
Resolution range (Å) 40.00-1.90 (1.93-1.90) 40.00-2.40 (2.44-2.40) 
Solvent content (%) 46 51 
No. of unique reflections 7348 (374) 19535 (962) 
Completeness (%) 95.5 (97.7) 99.2 (100.0) 
Redundancy 2.3 (2.2) 2.5 (2.5) 
〈 I/σ(I)〉 28.0 (3.5) 31.8 (2.3) 
Rmeasure 0.065 (0.368) 0.042 (0.607) 
Rp.i.m. 0.040 (0.233) 0.026 (0.368) 
Overall B factor from Wilson plot (Å2) 34.4 63.5 
CC1/2 (0.787) (0.876) 
Rcryst 0.165 (0.224) 0.231 (0.361) 
Rfree 0.211 (0.291) 0.261 (0.390) 
R.m.s. deviations   
      Bonds (Å) 0.013 0.010 
      Angles (°) 1.7 1.3 
Average B factors (Å2) 43.6 94.2 
Ramachandran plot   
     Favored (%) 97.7 96.6 
     Allowed (%) 2.3 3.4 




Table 2.2: Allergens from profilin family  
of proteins 
 
Allergens highlighted in: Gray-no complete 
sequence available, White- Tm <55 °C, 
Orange-Tm 55-65 °C, and Red Tm >65 °C.
Name Source Common Name Allergen Source Tm Prediction
Aca f 2.0101 Needle Bush <55
Act d 9.0101 Green Kiwi Fruit Fruit
Aeq ta 12 Tauch's Goatgrass <55
Ama r 2.0101 Redroot Pigweed Pollen <55
Ama v 2.01 Slender Amaranth Pollen <55
Ama v 2.02 Slender Amaranth Pollen <55
Amb a 8.0101 Short Ragweed Pollen <55
Ana c 1.0101 Pineapple Stem <55
Api g 4.0101 Celery Root <55
Ara h 5.0101 Peanut Seed <55
Art v 4.0101 Mugwort, Wormwood Pollen <55
Art v 4.0201 Mugwort, Wormwood Pollen <55
Beta v 2.0101 Sugar Beet Pollen
Bet v 2.0101 Birch Pollen <55
Blo t 36 Mites Whole body <55
Bra n 8 Canola, Rapeseed Pollen <55
Cap a 2.0101 Chilli Pepper, Bell Pepper Fruit 55-65
Car mi 2 Florida Royal Palm Pollen <55
Che a 2.0101 Lambsquarters Pollen <55
Citr l 2.0101 Watermelon Fruit 55-65
Cit s 2.0101 Sweet Orange Fruit <55
Coc n 5 Coconut Pollen <55
Cor a 2.0101 Birch, Hazelnut, Oak Pollen, Seed 55-65
Cro s 2.0101 Saffron Crocus Pollen, Stigma <55
Cuc m 2.0101 Canteloupe, Muskmelon Fruit 55-65
Cyn d 12.0101 Bermuda Grass Pollen <55
Dau c 4.0101 Carrot Root <55
Fra a 4.0101 Strawberry Fruit <55
Gly m 3.0101 Soybean Seed 55-65
Hel a 2.0101 Sunflower Pollen <55
Hev b 8.0101 Latex Latex <55
Hev b 8.0201 Latex Latex <55
Hor v 12.0101 Barley Pollen <55
Jug r 7.0101 English Walnut Seed
Koc s 2.0101 Burning Bush Pollen <55
Lit c 1.0101 Lychee Fruit <55
Lup a 5.0101 White Lupine Seed <55
Mal d 4.0101 Apple Fruit <55
Mal d 4.0201 Apple Fruit 55-65
Mal d 4.0301 Apple Fruit <55
Man i 3.01 Mango Fruit <55
Man i 3.02 Mango Fruit <55
Mer a 1.0101 Annual Mercury Pollen <55
Mus a 1.0101 Banana Fruit <55
Ole e 2.0101 Olive Pollen <55
Ory s 12.0101 Rice Pollen, Seed <55
Par j 3.0101 Pellitory-of-the-Wall Pollen <55
Par j 3.0201 Pellitory-of-the-Wall Pollen 55-65
Pha v 5 Bean, French Bean, Kidney BeanS ed 55-65
Phl p 12.0101 Timothy Grass Pollen <55
Pho d 2.0101 Date Palm Pollen <55
Pla l 2.0101 English Plantain Pollen
Pro j 2.0101 Mesquite Pollen <55
Pru av 4.0101 Sweet Cherry Fruit 55-65
Pru du 4.0101 Almond Seed 55-65
Pru p 4.0101 Peach Fruit 55-65
Pru p 4.0201 Peach Fruit <55
Pyr c 4.0101 Pear Fruit <55
Sal k 4.0101 Russian Thistle, Saltwort Pollen
Sal k 4.0201 Russian Thistle, Saltwort Pollen <55
Sin a 4.0101 Yellow Mustard Seed <55
Sola l 1.0101 Tomato Fruit 55-65
Sola t 8 Potato Tuber 55-65
Sor b 12 Sorghum Pollen <55
Tri a 12.0101 Wheat Pollen, Seed <55
Tyr p 36.0101 Storage Mite Whole body 55-65
Vit v 4 Grape Fruit >65






Figure 2.1: Sequence similarities and identities between Cuc m 2.0101 and various 
plant profilins. All proteins are officially registered as allergens by the World Health 
Organization and International Union of Immunological Societies (WHO/IUIS) Allergen 
Nomenclature Sub-committee (www. allergen.org). Proteins are colored according to 






Figure 2.2: Profilins Project Flow Chart. Steps taken to  





Figure 2.3: SEC Elution Profile for Cuc m 2.0101. (A) Presence of profilins in the 
marked peaks was confirmed using SDS-PAGE. (B) The SEC results indicate that both 
monomeric and dimeric forms of Cuc m 2.0101 are generated during production of these 
recombinant proteins. The elution profile for Art v 4.0101 (data not shown) is exactly the 





Figure 2.4: DSF results for Cuc m 2.0101 and comparison to Art v 4.0101. (A) Average 
melting temperatures (Tm in °C) for Cuc m 2.0101 with and without purification tag. A 
gradient of salt (0.0−1.0M NaCl) and pH (4.0−9.5) buffers were used. Yellow, green, and 
blue represent high, average, and low melting temperatures, respectively. (B) Melting 
temperature (Tm in °C) differences between Cuc m 2.0101 and Art v 4.0101 for proteins 
with and without purification tag. Yellow, green, and blue represent high, average, and low 
melting temperature differences respectively. The standard deviation was less than 1°C for 





Figure 2.5: DSF Results for Phl p 12.0101 and comparison to Amb a 8.0101, Ar v 
4.0101 and Bet v 2.0101. (A) Average melting temperatures (Tm in °C) for rPhl p 12.0101 
with and without purification tag. Yellow and blue represent high and low melting 
temperatures, respectively. (B) Melting temperature (Tm in °C) differences between rPhl 
p 12.0101 and rAmb a 8.0101. (C) Melting temperature differences between rPhl p 12.0101 
and rArt v 4.0101. (D) Melting temperature differences between rPhl p 12.0101 and rBet 
v 2.0101. Yellow and blue represent high and low differences in the melting temperatures, 






Figure 2.6: Structure of Art v 4.0101. Sequence identity and similarity between Art v 
4.0101 and Cuc m 2.0101 shown on the Art v 4.0101 structure (PDB code 6B6J). The top 
images are cartoon representation with the cysteine residues shown in stick representation 
while the bottom images show surface representation. In Cuc m 2 there is no cysteine that 
corresponds to Cys95 of Art v 4. This amino acid is replaced by Thr residue and therefore 
no internal disulfide bridge is present in Cuc m 2. Grey indicates identical residues, and 
green is used to marked residues that are similar, but not identical. Regions displayed in 




Figure 2.7: Sequence conservation in all allergenic 
profilins in the PDB. (A) Secondary structure elements are 
marked for Zea m 12.0101 (PDB code 5FEF) and Art v 
4.0101 (PDB code 6B6J), respectively. Cysteine residues 
forming disulfide bridges in Amb a 8.0101 and Art v 4.0101 
are marked using green boxes. (B) Conservation of profilin 
sequences mapped on structure of Cuc m 2.0101 presented 
in cartoon representation. Residues that are conserved in all 
analyzed allergenic profilins herein (Table 2.2) are marked 
in red. Residues from profilins that have their structures 
determined and are completely conserved are shown in red 
and salmon. It implicates that salmon corresponds to 
residues that are conserved for profilins shown in this 
figure, but which are not completely conserved among all 
analyzed profilins. N- and C-terminal residues are marked 
with corresponding letter. (C) Conservation of sequences 





Figure 2.8: Identified epitopes and mimotope for Cuc 
m 2.0101. [83] (A) Cartoon (top) and surface (bottom) 
representations of Cuc m 2.0101 with mapped IgE 
epitopes as determined by Lopez-Torrejon et al. [121]. 
N- and C-terminal residues are marked with 
corresponding letters. Epitope 1, consisting of residues 
66–75 and 81–93, in wheat, epitope 2 (residues 95–99 
and 122–131) in brown, epitope 3 (residues 2–10) in 
light teal, and epitope 4 (residues 35–45) in light pink. 
(B) Mimotope determined by Tordesillas et al. and 
consisting of residues 2–3, 5–6, 9–10, 111–114, 116–





Figure 2.9: Dimeric and monomeric profilins. (A) Dimeric structure of Hev b 8.0101. 
(B) Cuc m 2.0101 (surface representations) superposed on one of the molecules forming 
Hev b 8.0101 dimer. Epitope 1 is marked in wheat, epitope 2 in brown, epitope 3 in light 
teal and epitope 4 in light pink. (C) Cuc m 2.0101 with modeled polyproline peptide 
(shown in sphere representation). The peptide binding site is formed by residues forming 
epitopes 2 and 3 identified by Lopez-Torrejon et al. [121] (D) Mimotope determined by 
Tordesillas et al. [131] (light blue). Cys residues that may be responsible for formation of 
a dimeric structure is marked in orange. (E) Putative Cuc m 2.0101 dimer interface based 
on structure homology of Hev b 8 (PDB code 5FEG). Residues marked in blue are 







Figure 2.10: Representative results of ELISA inhibition assay. IgE 
binding to Amb a 8.0101, Art v 4.0101, Bet v 2.0101, and Phl p 12.0101 
of a serum with predominant sensitization to Art v 4 was tested. 
Increasing concentrations of either (A) Phl p 12.0101 or (B) Art v 






Figure 2.11: Comparison of Amb a 8, Art v 4, Bet v 2, and 
Phl p 12 sequences. All isoallergens reported by the World 
Health Organization (WHO) and International Union of 
Immunological Societies (IUIS) Allergen Nomenclature Sub-
committee (allergen.org) are shown. (A) Sequence alignment 
generated using Clustal Omega [17] and ESPript [18]. (B) 
Sequence identities and similarities between the profilins as 
calculated by SIAS (http://imed.med.ucm.es/Tools/sias.html) 





A ROBUST METHOD FOR THE ESTIMATION AND VISUALIZATION 
OF IGE CROSS-REACTIVITY LIKELIHOOD BETWEEN ALLERGENS 
BELONGING TO THE SAME PROTEIN FAMILY1
 
3.1 INTRODUCTION TO A-RISC INDEX 
As scientists not only are we interested in mitigating allergic reactions as discussed 
in the previous chapters, but we are also committed to stopping them before they even 
happen. In the quest to rid mankind of allergic diseases, significant amounts of time have 
been invested in studying the cause of allergic diseases. Centuries of research in the human 
immune system mechanisms and functions, as well as, on the development of allergic 
diseases has established an irrefutable fact that immunoglobulin E, IgE, is the instigator of 
most of the diverse and sometimes fatal allergic reactions associated with allergic diseases 
[27]. IgE immune responses are called “immediate hypersensitivity,” and this depiction not 
only denotes the extreme nature of IgE sensitivity to allergens, but also the tremendous 
speed in which the immune response takes place [27]. 
 
_________________________________ 
1 Chruszcz M., Kapingidza A. B., Dolamore C. and Kowal K. 2018. PloS One 13 (11):    
   e0208276  





Interactions between IgE and allergens are crucial for allergic diseases, as the 
formation of an allergen-antibody complex is necessary for triggering an allergic reaction. 
The IgE-mediated allergic reaction requires an allergen to cross-link antibodies bound to 
the high-affinity receptors located on mast cells [8]. Therefore, in molecular allergology 
there is significant effort directed to understanding interactions between allergens and 
antibodies [132,133]. For example, such efforts aim to identify IgE binding epitopes and 
epitope-paratope interactions [133].  Although allergen-antibody interactions may be 
studied using various methods, structural biology provides one of the best insights into this 
molecular phenomenon [43]. Thanks to advancements of X-ray crystallography and NMR, 
we can picture epitopes as being relatively small fragments of proteins recognized by 
antibodies. Structural biology also provides insight on the structures of many allergens 
[43,133]. Therefore, in most cases, it is possible through homology modeling to elucidate 
information on the tertiary structure of these molecules provided that the protein sequence 
is available.  
Because, IgE binding epitopes are conformational, they can experience substantial 
cross-reactivity with proteins of high sequence identity, especially of surface residues. 
Cross-reactivity occurs when antibodies raised against one allergen, cannot distinguish 
between that allergen and a structurally similar protein, and thus, binds to the secondary 
protein [134].  In the process to understand cross-reactivity between allergens, a minimal 
approach may use only the information on sequence identity for an estimation of a cross-
reactivity likelihood; or combine such information with phylogenetic analysis leading to 
the elucidation of evolutionary relation between allergens that are recognized by the same 




than 70% sequence identity and is rare when the sequence identity falls below 50% [135]. 
Evidently, these simple rules appear to help in effectively predicting the observed IgE 
cross-reactivity. However, the comparison of allergens, and especially the prediction of 
allergenicity, can be significantly more complex than desired as there are various dedicated 
computational tools that allow us to perform such analysis [136,137]. 
Nonetheless, here [9] we introduced a simple approach, the A-RISC Index 
(Allergens’–Relative Identity, Similarity and Cross-reactivity), that uses information on 
the primary structures of allergens in combination with various assumptions and 
observations related to their interactions with antibodies. The A-RISC index is a single 
numerical value used to predict the likelihood of IgE cross-reactivity of two allergens 
belonging to the same protein family. The A-RISC index takes advantage of the fact that 
some allergens’ families have many identified and characterized members which in turn 
allows us to derive more precise guidelines to estimate the likelihood of cross-reactivity 
between members of the same protein family. It must be stressed that we focused on cross-
reactivity (we assume that there was one sensitizing allergen), and we are not interested in 
multi-sensitization, as the multi-sensitization refers to the generation of unrelated IgE 
responses [138]. It is also assumed that in the case of allergy we face the polyclonal cross-
reactivity [139]. Moreover, we concentrate on cross-reactivity between allergens belonging 
to the same protein family that share the same overall fold.  
In our PloS One article [9], we presented cross-reactivity analysis of ten allergen 
families using the A-RISC index and contrast our findings with reports on IgE cross-
reactivity determined using experimental approaches. However, in this manuscript only 




profilins will be discussed. Our approach to the analysis of allergens’ sequences not only 
considers possible interactions with antibodies, but also results in a single numerical value 
that describes the likelihood of cross-reactivity between two allergens originating from the 
same family of proteins. Based on our analysis, we proposed the introduction of four 
categories describing a risk of a cross-reactive reaction, namely: high, medium-high, 
medium-low, and low. We believe that this proposed model is a better estimate of possible 
cross-reactivity for pairs of allergens having low or medium levels of sequence identity. 
Moreover, the proposed approach may facilitate analysis in component-resolved allergy 
diagnostics and generation of avoidance guidelines for allergic individuals or help with the 
design of immunotherapy. 
3.2 SELECTION OF ALLERGENS 
 The selected allergen families had at least 13 representative proteins and overall 
folds that differ significantly [9], but also include relevant allergens with various potencies 
(Table 1). Protein sequences were obtained by searching Allfam [3], Allergome [140] and 
Allergen Nomenclature databases [141]. Only proteins with complete sequences were 
considered. Furthermore, the sequences used for analysis correspond to the mature version 
of proteins (signal- and pro-peptides were omitted). This study included allergens that are 
registered by the World Health Organization and International Union of Immunological 
Societies (WHO/IUIS) Allergen Nomenclature Sub-committee (www.allergen.org) as well 
as allergens that are listed by Allergome and/or Allfam and not officially registered.  
In case of officially registered allergens, the full nomenclature name which includes 
four digits after a period in the numerical part of an allergen symbol was used [141]. Many 




the same digit in the second place, only one representative sequence was chosen and, most 
often, it was the isoallergen with full nomenclature name ending with a 1. This approach 
is related to the fact that currently the third and fourth digits of the nomenclature name are 
determining variants of an isoallergen, with the variant usually having more than 90% 
sequence identity [141]. However, in some cases when a full sequence for such a protein 
was not available, isoallergens with names having 2 in the fourth place after the period 
were chosen. The selected sequence of allergens belonging to each family were stored in 
Fasta format.  
3.3 ANALYSIS OF SEQUENCES  
Multiple sequence alignment of proteins belonging to a single family were 
performed with clustal Omega [130]. Sequence similarities and identities were calculated 
with SIAS (http:// imed.med.ucm.es/Tools/sias.html) using the default parameters. The 
SIAS webpage divides amino acids into the following similarity groups: aromatic (F, Y 
and W), aliphatic (I, L and V), positively charged (H, K and R), negatively charged (D and 
E), small with hydroxyl group (S and T) and neutral polar (N and Q). The five remaining 
amino acids (A, C, G, M and P) are not included to any similarity groups. Sequence 
similarities and identities calculated with SIAS were stored and used for the generation of 
various plots as well as for A-RISC calculations (Allergens’–Relative Identity, Similarity 
and Cross-reactivity) indexes. In the manuscript [9], an A-RISC index for a particular pair 
of proteins is defined as an average of the proteins’ sequence similarity (S), as calculated 
by SIAS server, and identity (1). The index we propose is a single numeric value that 
provides information on relative homology between allergens from a particular protein 




of the A-RISC index can be explained by considering interactions of these proteins with 
antibodies [9]. For example, most epitope and paratope recognition is mediated by 
hydrogen bonds, hydrophobic interactions and shape complementarity. The presence of the 
same or similar amino acids in the corresponding regions of two proteins may lead to a 
situation whereby the same antibody will fail to discriminate between the proteins, as the 
paratope will be able to form interactions with the same or similar epitopes that are present 
in both proteins (allergens).  
In this model, we made several assumptions that allow for the simplification of the 
comparison of two allergens as well as allergen-antibody interactions. For example, we use 
only information on allergen sequences (primary structure) and ignore secondary and 
quaternary structures. The only assumption on the tertiary structurers is related to the fact 
that proteins from the same family generally adopt the same overall fold. Furthermore, we 
presume that when two protein sequences are compared, we can divide the compared 
amino acids into three groups: identical, similar, and not similar. We define similar as: 
“similar” = “identical” + “similar, but not identical”. Additionally, we assume that in the 
case of two allergens belonging to the same protein family, only identical and similar amino 
acids are responsible for cross-reactivity. We also make an assumption that in the cases of 
non-identical, but similar amino acids, only in 50% of cases will we observe participation 
of these residues in binding of a cross-reactive antibody. The previous two assumptions 
allow us to write the following equation that describes a fraction of all amino acids which 











and provide the formula for calculation of the A-RISC index. In the equation I stands for 
Identical residues and S, similar but not identical residues. An example of the proposed 
here comparison of two allergens is illustrated in Figure 3.1. One should note that the 
difference between A-RISC and sequence identity (expressed as fraction) values will be 
small for pairs having high sequence identity. However, A-RISC values will be 
significantly higher than corresponding identities for pairs of proteins with low or medium 
sequence identities. Using the above mentioned formula, the likelihood of IgE cross-
reactivity between the three protein families, papain-like cysteine proteases, Niemann-Pick 
proteins type C2 (NPC2) and profilins, discussed in this manuscript were calculated and 
the results compared to experimental findings annotated in literature.  
3.4 A-RISC INDEX FOR PAPAIN-LIKE CYSTEINE PROTEASES 
This is the family where Group 1 HDM allergens (Der p 1 and Der f 1), discussed 
earlier in chapter 1, belong. In their mature form, the papain-like cysteine proteases (clan 
CA and family C1) [142] are monomeric proteins composed of approximately 220 amino 
acids [30]. The active site is located between two globular domains (Figure 3.1B), and the 
proteolytic activity of these enzymes was reported to contribute to their allergenicity [22]. 
There are several human homologs of these proteins, like cathepsins, that have a similar 
overall architecture, but have a relatively low sequence identity exemplified by human 
cathepsin K, which is most similar to Der f 1, as the enzymes share 36% of identical 
residues [73]. This family of allergens contains proteins originating from both animals and 
plants. Eleven of these proteins originate from mites (Group 1 mite allergens), one from a 
tick (Boo m 1) and three from plants (Act d 1, Amb a 11 and Ana c 2). The allergens from 




The most frequently recognized allergens from this protein family are excreted by 
the HDM, Der p 1 and Der f 1 [143]. Analysis of the relative sequence identities and 
similarities, as well as the plots with A-RISC index (Figure 3.2A) clearly show that Der p 
1, Der f 1, and Eur m 1 are similar, and thus, there is a high risk of IgE cross-reactivity 
between these proteins. Conversely, there is a significantly lower chance of cross-reactivity 
between the three HDMs allergens and other members of the allergen family [9]. The only 
exemption is Pso o 1 that has ~64% sequence identity and ~70% similarity to Der p 1, Der 
f 1 and Eur m 1, and therefore has a significant chance to be involved in a cross-reactive 
reaction with the aforementioned allergens [144]. In addition, our analysis shows that in 
case of individuals that were sensitized with Blo t 1.0101 there is a relatively low risk of a 
cross-reactive reaction with other cysteine proteases presented therein (Figure 3.2B).  
Interestingly, in the case of Blo t 1, the difference in sequence between isoallergens 
(Blo t 1.0101 and Blo t 1.0201) is quite significant. This also clearly highlights differences 
between proteins originating from HDMs and storage mites and is consistent with limited 
cross-reactivity between these allergens observed among mite allergic individuals 
[145,146]. Figure 3.2B also suggests that a cross-reactive reaction between Blo t 1 is more 
likely to be observed with Sui m 1 (Suidasia medanensis), Tyr p 1 (Tyrophagus 
putrescentiae) and Aca s 1 (Acarus siro) than with Der p 1 or Der f 1. This observation is 
consistent with results of cross-reactivity between allergens from S. medanensis and B. 
tropicalis reported for an urban area of Cartagena (Spain) [147]. In this report, according 
to RAST and immunoblot inhibition experiments, a significant inhibition of IgE binding to 





The analysis of A-RISC indexes for the whole family of allergens (Figure 3.3) 
shows a low risk of cross-reactivity between allergens originating from mites and plants. 
The highest risk of cross-reactivity is related to proteins originating from HDMs, whilst 
that of proteins from storage mites is lower, as they are less similar between themselves. 
Data presented in Figure 3.3 also indicate a medium-high risk of cross-reactivity between 
proteins from Aleuroglyphus ovatus (Ale o 1, brown legged grain mite) and Boophilus 
microplus (Boo m 1, southern cattle tick). 
3.5 A-RISC INDEX FOR NPC2 FAMILY 
NPC2 (NPC intracellular cholesterol transporter 2, Niemann-Pick proteins type C2) 
is the family where Group 2 HDM allergens (Der p 2 and Der f 2), discussed in chapter 1, 
belong to. Proteins belonging to the NPC2 family are composed of approximately 130 
amino acids that form a single β-sandwich domain (immunoglobulin-like tertiary structure) 
[44,148]. These proteins do not have an enzymatic activity, but they are able to 
accommodate various ligands [149]. Human NPC intracellular cholesterol transporter 2 
shares 25% of identical residues with Der p 2 and was shown to mimic human MD-2, a 
liposaccharide binding component of Toll-like receptor 4 signaling complex. This 
molecular mimicry is most likely responsible for Der p 2 allergenicity [25].  
NPC2 proteins are present in arthropods and vertebrates [150], however, allergens 
from this family originate primarily from mites (Group 2 mite allergens) with only two 
allergens that have a different source (Can f 7 – dog and Ixo r 2 – castor bean tick). 
Currently, neither food nor plant allergens are reported as being members of this family. 
Analysis of relative sequence homology shows a situation similar to the case of the cysteine 




80% and sequence similarities over 90%. Other allergens have less than 50% sequence 
identity when compared to Der p 2.0101 (Figure 3.4A). At the same time, Blo t 2 (Figure 
3.4B) is quite distinct from other members of the family with Sui m 2 and Der f 35 having 
the highest sequence identity of 56% and 52% respectively. Analysis of the sequences of 
proteins originating from HDMs and storage mites is consistent with observed clinical 
cross-reactivity. It was shown that there is limited cross-reactivity between Group 2 
allergens from D. pteronyssinus and B. tropicalis, Glyciphagus domesticus or 
Lepidoglyphus desctructor; while there is cross-reactivity between Lep d 2, Gly d 2 and 
Tyr p 2 [151-153]. These observations are in agreement with our results as depicted on 
Figures 3.4 and 3.5. On the other hand, it was shown that cross-reactivity between Der p 2 
and Tyr p 2 may be quite significant [154], despite the sequence identity being below 40%. 
Furthermore, our analysis reveals that the highest potential risk of cross-reactivity between 
Group 2 mite allergens originating from HDMs and Blo t 2.0101 is associated with Der f 
35, and not Der f 2, Der p 2 or Der f 22 (Figure 3.6). 
There are three allergens belonging to the NPC2 family and originating from D. 
farinae: Der f 2, Der f 22 (33%/40% of sequence identity/similarity to Der f 2) and Der f 
35 (41%/57% of sequence identity/similarity to Der f 2). Both Der f 2 and Der f 35 are 
considered to be major allergens, while Der f 22 is a minor allergen [155]. Using these 
allergens as examples it can be shown that proteins could have quite distinct sequences 
despite belonging to the same family and originating from a single organism (Figures 3.4A 
and 3.5). Conversely, the presence of several allergens in one source may cause a 
complicated pattern of cross-reactive reactions. For example, Der f 35 was shown to be not 




Our results also demonstrate that Can f 7 most likely will not be involved in cross-
reactive reactions in individuals that are sensitized with Group 2 mite allergens, because 
this dog allergen shares only 22-31% identical and 37-42% of similar residues with the 
corresponding mite allergens. A similar situation is observed for Ixo r 2 that shares only 
28-34% of identical and 41-50% of similar residues with the corresponding mite allergens.  
3.6 A-RISC INDEX FOR PROFILINS  
Profilins, the family where Cuc m 2, Art v 4 and Phl p 12 discussed in chapter 2 
belong, were identified as allergens almost four decades ago [116,156]. They are small 
(~130 amino acids), multifunctional proteins present in either a monomeric or dimeric form 
[116] with one of their most important features being their ability to interact with many 
proteins by binding to the poly-proline fragments [156]. Profilins are highly conserved in 
terms of their sequence (Table 3.1, Figure 3.7) and structure as they are considered to be 
the only true panallergens [10]. Profilins originating from plants are especially similar as 
they are responsible for various cross-reactive reactions [157]. This is consistent with our 
results as A-RISC index values for plant profilins are in 0.73-0.99 range. The two profilins 
originating from storage mites (Blo t 36 and Tyr p 36) are similar to each other, but they 
significantly differ in sequence when compared to plant profilins (Figures 3.7 and 3.8). 
Allergens from this family are structurally similar to human profilins, however sequence 
identity with human homologs is smaller than 25% [88,158]. 
The most common reactions involving allergens from the profilin family are 
associated with Oral Allergy Syndrome (OAS; also known as Pollen-Food Syndrome) 
which is considered a class II food allergy. In this syndrome, an allergen from pollen is the 




OAS may be explained using Figure 3.8 as an illustration. In this case, it is assumed that 
birch pollen profilin (Bet v 2.0101) is responsible for the sensitization, and due to the high 
homology with food profilins such as apple (Mal d 4.0301), pear (Pyr c 4.0101), carrot 
(Dau c 4.0101), and celery (Api g 4.0101), cross-reactive reactions are observed. This is 
also reflected by clinical sensitization patterns. In Northern Europe, where sensitization to 
birch allergen is common, Bet v 1 and Bet v 2 are responsible for birch-celery syndrome.  
A similar situation is observed in the case of OAS involving birch and apple, where 
other allergen families like PR-10 and profilin allergens are involved in cross-reactive 
reactions [160]. In the areas where there is no exposure to birch allergens, profilins from 
weeds (Amb a 8 and Art v 4), grass (Phl p 12), olive (Ole e 2) or date palm (Pho d 2) may 
replace Bet v 2 as potential sensitizing allergens [161,162]. This results in various pollen-
food syndromes including mugwort-celery, mugwort-peach, ragweed-melon-banana, 
grass-fruit and plant-fruit. [91,121,122,163]. In summary, the comparison of profilins 
sequences not only shows why cross-reactivity between these allergens is so wide-spread, 
but also explains the high-risk of such events. It also shows why using one profilin may be 
sufficient in diagnosing sensitization to all other plant profilins [5,112] 
3.7 DISCUSSION  
Sequence Identity and A-RISC Index 
The analysis of the ten allergen families presented herein [9] showed that even 
simple models that are based on protein sequences may be very helpful in understanding 
molecular bases of cross-reactivity. Moreover, such analysis can provide an explanation 
for clinically observed cross-reactivity patterns. In our opinion, analysis of sequence 




Introduced here, the A-RISC index is a step forward towards a better estimation of 
the likelihood of cross-reactivity, and when combined with structural information, 
illustration of the homology between pairs of allergens can be better elucidated (Figures 
3.1 and 3.9). Moreover, it clearly shows why similar, but not identical residues can play a 
role in cross-reactivity, especially for proteins that have a relatively low sequence identity 
(Figure 3.9). For example, only consideration of identical and similar residues combination 
explains why a cross-reactive reaction between Bet v 1 and Act d 11 may be observed 
[164]. In this case, we are able to explain the formation of continuous patches on the surface 
of Act d 11 that may correspond to epitopes responsible for binding IgE antibodies 
developed against Bet v 1 [164]. Such surface patches corresponding to epitopes usually 
have an area of ~800 Å2 [133]. 
Despite various limitations, the model that we propose robustly predicts cross-
reactivity patterns that were extensively elucidated experimentally. Based on our analyses, 
we propose to amend the original rules for allergen cross-reactivity proposed by Aalberse 
[165] and introduce the four new following categories of cross-reactivity likelihood: high 
(A-RISC values  0.75), medium-high (0.75 > A-RISC  0.50), medium-low (0.50 > A-
RISC  0.25) and low (A-RISC values < 0.25).  
Allergen families that contain at least several members may be ranked according to 
their propensity for cross-reactive reactions. Such a ranking may be created by calculating 
an average A-RISC index for the whole family. For allergen families analyzed by us [9], 
but not all discussed in this manuscript (Figure 3.10), the propensity for cross-reactivity is 
as follows (average A-RISC indexes and sequence identities are reported in parenthesis): 




37%). It must be noted that this ranking corresponds to currently reported allergens, and 
patterns of cross-reactivity will strongly depend on allergen exposure.  
A-RISC index – Limitations of the Current Approach 
The A-RISC model, although a robust method for predicting IgE cross-reactivity 
between two allergens belonging to the same protein family, has various limitations. For 
example, this method considers sequences, whilst possible posttranslational modifications 
of the amino acids are ignored. Post-translational modifications resulting in the presence 
of hydroxyprolines, carbohydrates and other less common chemical moieties sometimes 
have a significant impact on the allergenic properties of proteins [10,166,167]. We also 
omit the fact that some of the ligands that are carried by allergens may impact the 
allergenicity of proteins. Moreover, even when considering only the protein sequence, we 
can improve the current approach by trying to map the sequence conservation on an 
allergen model and estimate whether the conserved residues that form patches or stretches 
are large enough to become epitopes (both continuous and discontinuous). As we do this, 
we might also need to consider that the conserved residues tend to cluster in parts of a 
protein important for the function and/or structure of the molecule. In addition, we did not 
incorporate any knowledge on IgE epitopes that was previously determined. Similarly, for 
allergen families like cysteine proteases or profilins, which have human homologs, we did 
not use these sequences of human proteins to adjust our model [168]. To improve the 
current A-RISC model these factors must be assimilated in the predictions. 
Applications of the A-RISC Index 
Currently, many diagnostic tools that can be used to detect IgE binding directed to 




great body of information concerning IgE binding to individual allergens. Understanding 
the cross-reactivity of individual allergenic proteins may help in explaining the results of 
allergy testing [169,170]. Therefore, we are convinced that the A-RISC index can be used 
to interpret results originating from component resolved allergy diagnostics. Considering 
the problem of allergen cross-reactivity that is often encountered in allergy diagnosis, 
analysis of IgE reactivity to individual allergens may allow for better selection of true 
sensitizers in patients allergic to multiple allergens.  
In addition, it may help to design appropriate composition of vaccines and 
immunotherapeutics used for allergy immunotherapy. Several reports provide evidence of 
how individual allergens present in vaccines may induce a protective immune response to 
cross-reactive allergens [171,172]. Moreover, the idea of analyzing allergens in the context 
of protein families, like in the calculation of A-RISC indexes, should provide better 
avoidance guidelines, as they may include not only information on molecules that are 
suspected to be the primary sensitizers, but also provide a list of allergens (and their 
sources) that may be involved in various cross-reactive reactions. Furthermore, the 
sequence derived guidelines, for example based on A-RISC indexes, are able to provide a 
general categorization of the likelihood of cross-reactivity. 
The analysis of allergen families also shows that due to their internal diversity, or 
lack thereof, proteins will be related to each other with completely different patterns of 
possible cross-reactivities. For example, allergenic profilins and serum albumins will be 
most likely associated with high likelihood of cross-reactivity, while it may be not true for 
other allergen families. It is also important to highlight that even in one allergen family, 




cross-reactivity. The categorization of the relative patterns of sequence identities and 
similarities may further facilitate prediction of the likelihood of cross-reactivity including 
allergenic proteins not yet characterized. 
In summary, the A-RISC index identifies true “allergen culprits” for patients with 
multiple allergies. Identifying true sensitizers will help design vaccines that are effective 
to all other cross-reactive allergens.  Our ultimate goal is to design an algorithm 
incorporating A-RISC indexes as part of a software that will help physicians to “navigate 
through the jungle of allergens” in order to provide accurate predictions for IgE cross-
reactivity thereby generating reliable avoidance guidelines for patients, and a good starting 






Table 3.1 Summary on sequence identity and similarities of papain-like cysteine 









Average sequence Range of sequence 












AF111 17 41% 58% 22-90% 34-95% 
Profilins AF051 64 76% 84% 32-99% 43-99% 
 




































 Figure 3.1: Comparison of Der p 1.0101 and 
Blot 1.0101. (A) Sequence alignment of Der p 
1.0101 and Blo t 1.0101 made with Clustal Omega. 
Similar residues are marked with bold font type. 
Identical residues-red, blue-the difference between 
similar and identical residues. (B) Similar amino 
acids (blue) marked on the structure of Der p 1. 
The structure is shown in ribbon (top) and space-
filling representation (bottom). (C) Identical 
amino acids (red) mapped on the structure of Der 
p 1. Residues marked in light blue correspond to 
the difference between similar and identical 
residues. We assume only 50% of these residues 





Figure 3.2: Relative homology and A-RISC indexes of allergens from the papain-like 
cysteine protease family. Comparison of other family members to Der p 1.0101 (A) and 
Blo t 1.0101. (B) Allergens originating from plants are shown in green. Red, gray and dark 
green dashed lines indicate 75%, 50% and 25% sequence identity and similarity 





Figure 3.3: A-RISC index values for allergen pairs from the papain-like cysteine 
protease family. Red color indicates a high risk of cross-reactivity, a dark green color 
indicates a low risk of cross-reactivity, and intermediate colors correspond to a medium 





Figure 3.4: Relative homology and A-RISC indexes of allergens from the NPC2 
family. Comparison of family members to Der p 2.0101 (A) and Blo t 2.0101. (B) Red, 
gray, and dark green dashed lines indicate respectively 75%, 50% and 25% sequence 





Figure 3.5: Relative homology and A-RISC indexes of allergens from the NPC2 
family. Comparison of family members to Der f 35.0101. (A) and Lep d 2.0101 (B) Red, 
gray, and dark green dashed lines indicate respectively 75%, 50% and 25% sequence 





Figure 3.6: A-RISC index values for allergen pairs from the NPC2 family. Red color 
indicates a high risk of cross-reactivity, a dark green color indicates a low risk of cross-





Figure 3.7: A-RISC index values for allergen pairs from profilin family of proteins. 
Red color indicates a high risk of cross-reactivity, a dark green color indicates a low risk 






Figure 3.8: Relative homology of allergens from profilin family. Comparison of family 
members to Bet v 2.0101. Only selected members of the family are labeled. Red and gray 
dashed lines indicate respectively 75% and 50% sequence identity and similarity, or 0.75, 





Figure 3.9: Comparison of Bet v 1.0101 with Act d 11.0101, Ara h 8.0101 and Cor a 
1.0101. Identical amino acids (red) mapped on the structure of Bet v 1. Residues marked 





Figure 3.10: A-RISC indexes for various allergen families. Gray bars correspond to 
observed A-RISC ranges. The black horizontal lines indicate an average A-RISC index for 





SUMMARY AND CONCLUSIONS 
There are more than a thousand allergens known to man emanating from different 
sources and these allergens are associated with various allergic diseases. This research in 
the Chruszcz laboratory, focused on aeroallergens from dust mites and pollens, as well as, 
food allergens. Among the most potent allergens in allergic diseases are dust mite allergens. 
Dust mites are arthropods that live in warm areas of high humidity and feed on human skin 
flakes. In households, dust mites are found almost everywhere including beds, carpets, and 
other furniture. Of the more than 35 groups of house dust mite (HDM) allergens registered, 
Group 1 and 2 HDM allergens elicit IgE response in more than 85% of sensitized 
individuals. These allergens affect 10-30% of the world’s population. Prolonged inhalation 
of low doses of HDM allergens by genetically predisposed individuals leads to the allergic 
diseases like asthma, rhinitis and atopic dermatitis.  
Among 85% of sensitized individuals, IgE-mediated immune response is elicited 
from two major dust mite species, Dermatophagoides farinae and Dermatophagoides 
pteronyssinus, and Der p 2 originates from the latter. We characterized the crystal structure 
of Der p 2 in complex with monoclonal antibody 7A1. We hypothesized that 
characterization of molecular and antigenic properties of allergens is necessary for the 
development of better allergy diagnostics and therapeutics. To test this hypothesis, we 




goal of the project was to produce hypo-allergens (allergen-mutants) that have considerably 
reduced binding to IgE antibodies which could be used for immunotherapy. 
The research was carried out in three steps: (1) Expression, purification and 
characterization of recombinant isoallergens (variants of the same allergen differing in one 
to three amino acid residues) and IgE/IgG antibody fragments (selected from 
combinational libraries designed from HDM allergic patients), (2) Identification of 
IgE/IgG epitopes on Group 2 allergens by generating antibody-antigen complexes, and (3) 
Design and production of modified Group 2 allergens with reduced IgE binding affinity. 
Since most IgE epitopes are conformational, X-ray crystallography provided detailed 
three-dimensional structural features of the IgE antibodies in complex with allergens, 
unveiling the important residues responsible for antibody-antigen interactions. Hence, after 
the identification of these “hot-spots,” using site-directed mutagenesis, two double mutants 
on the 7A1 epitope were generated.   
IgE binding affinities between the wild type natural and/or recombinant allergen 
and the mutants were compared using ELISA. As expected, the mutants had reduced 
binding to human IgE of 10-100-fold. These allergen mutants, hypoallergens, are good 
candidates in the development of HDM vaccines and immunotherapy. Two manuscripts 
originate from this project: “A Human IgE Antibody Binding Site on Der p 2 for the Design 
of a Recombinant Allergen for Immunotherapy” [26] published in Journal of Immunology 
and the second one is in preparation. Since most of the antibodies used in this research 
were IgG murine-derived monoclonal antibodies known to have overlapping epitopes with 
IgE, the next steps to this research aims to study allergen-antibody interactions in Group 2 




Another class of allergens we studied in this research are profilins. Profilins are 
small, 12-15 kDa, ubiquitous proteins that bind poly-L-proline (PLP) fragments, which 
allows interaction with actin. Profilins share high sequence identity and similarity, as well 
as, extremely conserved three-dimensional structures even across distant species. This 
renders them as panallergens—minor allergens widespread in pollens and foods, and 
responsible for immunoglobulin E cross-reactivity. Cross-reactivity occurs when the 
antibodies raised against one allergen, cannot distinguish between that allergen and a 
structurally similar protein, and thus, binds to the secondary protein. This cross-reactivity, 
as well as others, leads to syndromes such as pollen-food syndrome. Various fruits, 
vegetables and nuts share similar proteins with pollen. When IgE antibodies specific to a 
particular pollen cross react with a type of food ingested by an individual, it triggers an 
inflammatory reaction that will lead to an allergic reaction— characterized by symptoms 
in the skin, gastro-intestinal tract, oral itching and labial edema, or respiratory system.  
Although profilins are mainly regarded as minor allergens, they are important 
players in IgE cross-reactivity leading to various allergic diseases including pollen-food 
syndrome. In this research, the structural, molecular, and thermal stability characteristics, 
as well as, possible IgE cross-reactivity between profilins were investigated. Among other 
profilins characterized, Cuc m 2, a profilin from Cucumis melo (muskmelon), Art v 4 from 
Artemisia Vulgaris (mugwort) and Phl p 12, a profilin from Phleum pratense (Timothy 
grass), were recently studied. While most profilins are minor allergens, Cuc m 2 is a major 
allergen since it can elicit IgE production in 80% of sensitized individuals. In addition, it 
has high sequence and structure similarity to other major allergens like Art v 4 and Hev b 




Comparison of profilins molecular, structural and antigenic properties provides new 
insights into the allergenicity of this family of proteins, expedite allergy diagnostics and 
facilitate the development of hypoallergenic molecules that can be exploited in 
immunotherapy. Results generated in this part of the project were published in two 
manuscripts: “Comparative structural and thermal stability studies of Cuc m 2.0101, Art v 
4.0101 and other allergenic profilins” in Molecular Immunology [83] and “Production and 
Use of Recombinant Profilins Amb a 8, Art v 4, Bet v 2, and Phl p 12 for Allergenic 
Sensitization Studies” in Molecules [84]. The future directions to the profilin family project 
is to study how the oligomeric state of the allergen influence the allergenicity of profilins 
and how these oligomeric states alter or influence IgE binding. 
As scientists not only are we interested in mitigating allergic reactions, but also in 
stopping them before they even happen. In 2018, we proposed a new way of predicting IgE 
cross-reactivity, the A-RISC index (Allergens’–Relative Identity, Similarity and Cross-
reactivity). In our PLOS One article, “A robust method for the estimation and visualization 
of IgE cross-reactivity likelihood between allergens belonging to the same protein family,” 
[9] four categories (high, medium-high, medium-low and low) predicting the likelihood of 
IgE cross-reactivity between proteins belonging to the same family were introduced.  
The A-RISC index identifies true “allergen culprits” for patients with multiple 
allergies. Identifying true sensitizers will help design vaccines that are effective to all other 
cross-reactive allergens.  Our main goal is to design an algorithm incorporating A-RISC 
indexes as part of a software that will help physicians to “navigate through the jungle of 
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